Amphastar Pharmaceuticals (AMPH) 10-K 15 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 08, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Amphastar Pharmaceuticals, Inc.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	1,297,184
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Common Stock, Shares Outstanding		45,910,116
Entity Public Float			$ 570,095,519

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 72,354	$ 66,074
Short-term investments	527
Restricted short-term investments	1,390	1,285
Accounts receivable, net	26,777	33,233
Inventories, net	79,754	70,665
Income tax refund and deposits	22	238
Prepaid expenses and other assets	3,272	4,439
Total current assets	184,096	175,934
Property, plant, and equipment, net	152,944	142,161
Goodwill and intangible assets, net	50,307	39,901
Other assets	9,390	4,696
Deferred tax assets	31,001	27,444
Total assets	427,738	390,136
Current Liabilities:
Accounts payable	16,196	13,872
Accrued liabilities	15,703	16,732
Income taxes payable	7,705	3,076
Accrued payroll and related benefits	13,847	12,840
Current portion of product return accrual	1,800	1,858
Current portion of deferred revenue		643
Current portion of long-term debt and capital leases	5,366	10,934
Total current liabilities	60,617	59,955
Long-term product return accrual	1,343	763
Long-term reserve for income tax liabilities	845	497
Long-term deferred revenue	97	1,339
Long-term debt and capital leases, net of current portion	32,356	30,165
Long-term deferred tax liabilities	1,455
Other long-term liabilities	1,770	1,907
Total liabilities	98,483	94,626
Stockholders’ equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 47,765,149 and 46,248,622 shares issued and outstanding as of December 31, 2016 and 45,960,206 and 45,198,491 shares issued and outstanding as of December 31, 2015, respectively	5	5
Additional paid-in capital	283,123	247,829
Retained earnings	70,855	60,323
Accumulated other comprehensive loss	(4,696)	(2,475)
Treasury stock	(20,032)	(10,172)
Total stockholders’ equity	329,255	295,510
Total liabilities and stockholders’ equity	$ 427,738	$ 390,136

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock; authorized shares	300,000,000	300,000,000
Common stock; shares issued	47,765,149	45,960,206
Common stock; outstanding shares	46,248,622	45,198,491

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Net revenues	$ 255,165	$ 251,519	$ 210,461
Cost of revenues	150,976	174,172	159,205
Gross profit	104,189	77,347	51,256
Operating expenses:
Selling, distribution, and marketing	5,466	5,470	5,564
General and administrative	41,832	41,504	34,809
Research and development	41,199	37,271	28,866
Total operating expenses	88,497	84,245	69,239
Income (loss) from operations	15,692	(6,898)	(17,983)
Non-operating income (expense):
Interest income	270	315	243
Interest expense	(1,024)	(987)	(609)
Other income (expense), net	8	(2,794)	201
Total non-operating income (expense), net	(746)	(3,466)	(165)
Income (loss) before income taxes	14,946	(10,364)	(18,148)
Income tax expense (benefit)	4,414	(7,577)	(7,449)
Net income (loss)	$ 10,532	$ (2,787)	$ (10,699)
Net income (loss) per share:
Basic (in Dollars per share)	$ 0.23	$ (0.06)	$ (0.25)
Diluted (in Dollars per share)	$ 0.22	$ (0.06)	$ (0.25)
Weighted-average shares used to compute net income (loss) per share:
Basic (in Shares)	45,375	44,961	41,957
Diluted (in Shares)	47,504	44,961	41,957

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	$ 10,532	$ (2,787)	$ (10,699)
Other comprehensive income (loss), net of income taxes
Foreign currency translation adjustment	(1,800)	(805)	(1,810)
Change in pension obligations	(421)	(16)	156
Total other comprehensive loss	(2,221)	(821)	(1,654)
Total comprehensive income (loss)	$ 8,311	$ (3,608)	$ (12,353)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2013	$ 4	$ 177,732	$ 73,809			$ 251,545
Balance at Dec. 31, 2013	38,765,940
Changes in Stockholders' Equity
Net (loss) income			(10,699)			(10,699)
Accumulated other comprehensive loss				$ (1,654)		(1,654)
Common stock issued through initial public offering		38,018				38,018
Common stock issued through initial public offering (in Shares)	5,840,000
Cost related to public offering		(3,358)				(3,358)
Treasury stock acquired					$ (345)	(345)
Treasury stock acquired (in Shares)					(29,400)
Issuance of common stock in connection with the Company's equity plans		182				182
Issuance of common stock in connection with the Company's equity plans (in Shares)	70,227
Share-based compensation expense		9,280				9,280
Tax effect of share-based compensation		(1,109)				(1,109)
Balance at Dec. 31, 2014	$ 4	220,745	63,110	(1,654)	$ (345)	281,860
Balance at Dec. 31, 2014	44,676,167				29,400
Changes in Stockholders' Equity
Net (loss) income			(2,787)			(2,787)
Accumulated other comprehensive loss				(821)		(821)
Treasury stock acquired					$ (9,865)	(9,865)
Treasury stock acquired (in Shares)					(735,679)
Issuance of treasury stock in connection with the Company's equity plans		(38)			$ 38
Issuance of treasury stock in connection with the Company's equity plans (in Shares)					3,364
Issuance of common stock in connection with the Company's equity plans	$ 1	14,200				14,201
Issuance of common stock in connection with the Company's equity plans (in Shares)	1,284,039
Share-based compensation expense		12,815				12,815
Tax effect of share-based compensation		107				107
Balance at Dec. 31, 2015	$ 5	247,829	60,323	(2,475)	$ (10,172)	$ 295,510
Balance at Dec. 31, 2015	45,960,206				761,715	45,198,491
Changes in Stockholders' Equity
Net (loss) income			10,532			$ 10,532
Accumulated other comprehensive loss				(2,221)		(2,221)
Treasury stock acquired					$ (9,908)	(9,908)
Treasury stock acquired (in Shares)					(759,067)
Issuance of treasury stock in connection with the Company's equity plans		(48)			$ 48
Issuance of treasury stock in connection with the Company's equity plans (in Shares)					4,255
Issuance of common stock in connection with the Company's equity plans		20,639				20,639
Issuance of common stock in connection with the Company's equity plans (in Shares)	1,804,943
Share-based compensation expense		15,124				15,124
Tax effect of share-based compensation		(421)				(421)
Balance at Dec. 31, 2016	$ 5	$ 283,123	$ 70,855	$ (4,696)	$ (20,032)	$ 329,255
Balance at Dec. 31, 2016	47,765,149				1,516,527	46,248,622

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities:
Net income (loss)	$ 10,532	$ (2,787)	$ (10,699)
Reconciliation to net cash provided by operating activities:
Loss on disposal and impairment of property, plant, and equipment	1,242	310	485
Depreciation of property, plant, and equipment	12,047	11,314	12,528
Amortization of product rights, trademarks, and patents	2,517	1,938	1,920
Imputed interest accretion	72	110	163
Share-based compensation	15,124	12,815	9,280
Reserve for uncertain tax positions	347	(1)	499
Changes in deferred taxes	(3,618)	(7,880)	(8,743)
Changes in operating assets and liabilities:
Accounts receivable, net	6,377	(11,012)	1,210
Inventories	(9,715)	9,775	6,565
Prepaid expenses and other assets	1,129	(699)	(88)
Income tax refund, deposits, and payable	3,329	(71)	2,432
Accounts payable and accrued liabilities	(823)	(3,131)	5,500
Net cash provided by operating activities	38,560	10,681	21,052
Cash Flows From Investing Activities:
Business Acquisitions	(12,461)		(18,352)
Purchases and construction of property, plant, and equipment	(21,382)	(16,047)	(20,499)
Proceeds from the sale of property, plant and equipment		51
Purchase of short-term investments	(3,602)
Maturity of short-term investments	3,075
Changes in restricted short-term investments	(105)	210	(170)
Payment of deposits and other assets	(5,026)	(1,139)	(752)
Net cash used in investing activities	(39,501)	(16,925)	(39,773)
Cash Flows From Financing Activities:
Net proceeds from equity plans	20,639	14,201	38,200
Excess tax benefit related to share-based compensation	863	107	(1,109)
Cost related to public offering			(1,920)
Purchase of treasury stock	(9,908)	(9,865)	(345)
Proceeds from borrowing under lines of credit			25,000
Repayments under lines of credit			(40,000)
Proceeds from issuance of long-term debt	10,198	6,785	26,505
Principal payments on long-term debt	(14,652)	(8,991)	(8,216)
Principal payments on short-term debt			(5,998)
Net cash provided by financing activities	7,140	2,237	32,117
Effect of exchange rate changes on cash	81	2,253	845
Net increase (decrease) in cash and cash equivalents	6,280	(1,754)	14,241
Cash and cash equivalents at beginning of period	66,074	67,828	53,587
Cash and cash equivalents at end of period	72,354	66,074	67,828
Noncash Investing and Financing Activities:
Equipment acquired under capital leases	1,238	150	78
Supplemental Disclosures of Cash Flow Information:
Interest paid, net of capitalized interest	1,722	1,941	2,607
Income taxes paid	$ 3,397	$ 146	$ 436

General

General	12 Months Ended
	Dec. 31, 2016
General
General	1. General Amphastar Pharmaceuticals, Inc., a California corporation, was incorporated on February 29, 1996 and merged with and into Amphastar Pharmaceuticals, Inc., a Delaware corporation, in July 2004 (together with its subsidiaries, hereinafter referred to as “the Company”). The Company is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation products will be primarily distributed through drug retailers once they are brought to market.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain amounts in the prior years’ consolidated statements of operations have been reclassified to conform to the current year presentation. This reclassification has no impact on net income or cash flows. All significant intercompany activity has been eliminated in the preparation of the consolidated financial statements. The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS; (2) Armstrong Pharmaceuticals, Inc., or Armstrong; (3) Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; (4) Nanjing Letop Fine Chemistry Co., Ltd., or Letop, (5) Amphastar France Pharmaceuticals, S.A.S., or AFP, (6) Amphastar UK Ltd., or AUK, and (7) International Medication Systems (UK) Limited, or IMS UK. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, provision for chargebacks, liabilities for product returns, adjustment to cost for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions. Foreign Currency The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary, ANP, and its U.K. subsidiary, AUK, is the U.S. dollar, or USD. ANP maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s statements of operations. The Company’s French subsidiary, AFP, Chinese subsidiary, Letop, and U.K. subsidiary, IMS UK, maintain their books of record in Euros, Chinese Yuan, and Great Britain Pounds, respectively, which are the local currencies and have been determined to be their respective functional currencies. These books are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the years ended December 31, 2016, 2015, and 2014 were a $1.5 million loss, $2.0 million loss, and a $2.7 million loss, respectively. Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure. Comprehensive Income (Loss) For the years ended December 31, 2016, 2015 and 2014, the Company included its foreign currency translation gain or loss and change in pension obligation of its defined benefit pension plan as part of its comprehensive income (loss). Shipping and Handling Costs For the years ended December 31, 2016, 2015, and 2014, the Company included shipping and handling costs of approximately $2.4 million, $2.6 million, and $2.5 million, respectively, in selling, distribution and marketing expenses in the accompanying consolidated statements of operations. Research and Development Costs Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company’s research and development activities including salaries and related employee benefits, costs associated with clinical trials, nonclinical research and development activities, regulatory activities, research‑related overhead expenses and fees paid to external service providers. The Company may produce inventories prior to or with the expectation of receiving marketing authorization in the near term, based on operational decisions about the most effective use of existing resources. This inventory is referred to as pre‑launch inventory. It is the Company’s accounting policy that the pre-launch inventory is capitalized if it has a probable future economic benefit. If marketing authorization is received and previously expensed pre‑launch inventory is sold, such sales may contribute up to a 100% margin to the Company’s operating results. Pre‑launch inventory costs include cost of work in process, materials, and finished drug products. As of December 31, 2016, 2015, and 2014, the Company did not have any capitalized pre-launch inventory. Financial Instruments The carrying amounts of cash and cash equivalents, short-term investments, restricted short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 12). The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values. Cash and Cash Equivalents Cash and cash equivalents consist of cash, money market accounts, money market funds, certificates of deposit and highly liquid investments purchased with original maturities of three months or less. Restricted Short‑Term Investments and Short-Term Investments Restricted short‑term investments as of December 31, 2016 and 2015 included $1.4 million and $1.3 million, respectively, in certificates of deposit, which are the collateral required for the Company to qualify for workers’ compensation self‑insurance and are available to meet the Company’s workers’ compensation obligations on a current basis, as needed. These funds are classified as current assets. The Company’s short‑term investments include municipal bonds with original maturities greater than three months and are classified as held-to-maturity. The municipal bonds are carried at amortized cost in the Company’s consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The Company does not intend to and will not be required to sell the investments before recovery of their amortized cost basis. Allowance for Doubtful Accounts Receivable The Company evaluates the collectability of accounts receivable based on a combination of factors. When the Company is aware of circumstances that may impair a customer’s ability to pay subsequent to the original sale, the Company records a specific allowance to reduce the amounts receivable to the amount that the Company reasonably believes to be collectable. For all other customers, the Company recognizes an allowance for doubtful accounts based on factors that include the length of time the receivables are past due, industry and geographic concentrations, the current business environment and historical collection experience. As of December 31, 2016 and 2015, the Company's allowance for doubtful accounts was $0.3 million and $0.7 million, respectively. Inventories Inventories consist of currently marketed products and products manufactured under contract. Inventories are stated at the lower of cost or net realizable value, using the first‑in, first‑out method. Provisions are made for slow‑moving, unsellable, or obsolete items. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. The charge of $7.3 million was included in the cost of revenues in the Company’s consolidated statements of operations for the year ended December 31, 2016 to adjust the Company’s inventory items to their net realizable value, including $3.1 million related to enoxaparin inventory items due to a decrease in the forecasted average selling price and $3.3 million related to Epinephrine Injection, USP vial inventory items and firm purchase commitments due to the anticipated discontinuation of the product. Property, Plant and Equipment Property, plant and equipment are stated at cost or, in the case of assets acquired in a business combination, at fair value on the purchase date. Depreciation and amortization expense is computed using the straight‑line method over the estimated useful lives of the related assets as follows: Buildings 20 - 31 years Machinery and equipment 2 - 12 years Furniture and fixtures 3 - 7 years Automobiles 4 - 5 years Leasehold improvements Lesser of remaining lease term or useful life Intangible Assets Intangible assets with finite lives are amortized using the straight-line method over the period the asset is expected to contribute directly or indirectly to the future cash flows of the Company as follows: Product rights 5 - 15 years Patents 10 - 20 years Land-use rights 37 - 50 years Impairment of Long‑Lived Assets, including Identifiable Definite-Lived Intangible Assets The Company reviews long-term assets and identifiable definite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets (assets to be held and used) or fair value less cost to sell (assets to be disposed of). The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share‑based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share‑based awards. Impairment of Indefinite-Lived Intangible Asset and Goodwill The Company reviews indefinite‑lived intangible asset and goodwill for impairment in the fourth quarter of each year or more frequently if indicators of impairment are present. When the Company chooses to perform a qualitative assessment, it evaluates economic, industry and company-specific factors as an initial step. If the Company determines it is more likely than not that the indefinite-lived intangible asset is impaired or the fair value of a reporting unit is less than its carrying amount, further quantitative impairment process is then performed; otherwise, no further testing is required. An impairment loss is recorded if the asset’s fair value is less than its carrying value. The Company also periodically reviews the indefinite-lived intangible asset to determine if events and circumstances continue to support an indefinite useful life. If the life is no longer indefinite, the asset is tested for impairment. The carrying value, after recognition of any impairment loss, is amortized over its remaining useful life. Self-Insured Claims The Company is primarily self-insured, up to certain limits, for workers’ compensation claims. The Company has purchased stop-loss insurance, which will reimburse the Company for individual claims in excess of $350,000 annually or aggregate claims exceeding $1.9 million annually. Operations are charged with the cost of claims reported and an estimate of claims incurred but not reported. A liability for unpaid claims and the associated claim expenses, including incurred but not reported losses, is actuarially determined and reflected in accrued liabilities in the accompanying consolidated balance sheets. Total expense under the program was approximately $1.6 million, $1.2 million, and $1.0 million, for the years ended December 31, 2016, 2015 and 2014, respectively. The self-insured claims liability was $3.5 million and $2.7 million at December 31, 2016 and 2015, respectively. The determination of such claims and expenses and the appropriateness of the related liability is reviewed periodically and updated, as necessary. Changes in estimates are recorded in the period identified. Business Combinations If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the asset acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to effect a business combination are expensed in the periods in which the costs are incurred. When the operations of the acquired businesses were not material to the Company’s consolidated financial statements, no pro forma presentation is disclosed. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required regarding customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). Based on the related accounting standards update issued in August 2015, this guidance will be effective for the Company in 2018, including interim periods within the year. While the Company is still in the process of evaluating the effect of adoption on its consolidated financial statements and is currently assessing its contracts with customers and sale of nonfinancial assets. The Company anticipates it will expand its consolidated financial statement disclosures in order to comply with the new guidance. The Company expects to select the modified retrospective transition method upon the adoption. In addition, in February 2017, the FASB issued an accounting standards update to clarify the scope of the model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets and to add guidance for partial sales of nonfinancial assets. This guidance is to be applied using a full retrospective method or a modified retrospective method as outlined in the guidance and is effective at the same time as discussed above. The Company is currently evaluating the provisions of this guidance and assessing its potential impact on the Company’s financial statements and disclosures. In July 2015, the FASB issued an accounting standards update which requires entities to measure most inventories at the lower of cost or net realizable value, or NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost or net realizable value, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company has elected to adopt the guidance early and apply the guidance prospectively in its interim quarter beginning October 1, 2016. The adoption of this accounting guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. In November 2015, the FASB issued an accounting standards update to the balance sheet classification of deferred taxes. Under existing standards, deferred taxes for each tax-paying jurisdiction are presented as a net current asset or liability and net long-term asset or liability. To simplify presentation, the new guidance will require that all deferred tax assets and liabilities, along with related valuation allowances, be classified as long-term on the balance sheet. As a result, each tax-paying jurisdiction will now only have one net long-term deferred tax asset or liability. The new guidance does not change the existing requirement that prohibits offsetting deferred tax liabilities from one jurisdiction against deferred tax assets of another jurisdiction. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The new guidance may be applied prospectively or retrospectively. The Company has elected to adopt the guidance early and apply the guidance prospectively. Therefore, prior periods were not retrospectively adjusted. The reclassification of the Company’s deferred tax assets and liabilities does not have any impact on the Company’s net income or cash flow; thus, the adoption of the guidance does not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued an accounting standards update that is aimed at making leasing activities more transparent and comparable, and which requires substantially all leases to be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements for the reporting periods in which the guidance is adopted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued an accounting standards update that is aimed at improving the employee share-based payment accounting. The standard update simplifies the accounting for employee share-based payments and involves several aspects of the accounting for share-based transactions, including the potential timing of expenses, the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The guidance is effective for annual periods during the year ended December 15, 2017, and interim reporting periods therein. Early adoption is permitted. The adoption of the guidance is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. In June 2016, the FASB issued an accounting standards update that is aimed at providing financial statement users with more useful information about the expected credit losses on financial instruments and other commitments to extend credit. The standard update changes the impairment model for financial assets measured at amortized cost, requiring presentation at the net amount expected to be collected. The measurement of expected credit losses requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Available-for-sale debt securities with unrealized losses will be recorded through an allowance for credit losses. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted for annual periods after 2019. The Company will be required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In August 2016, the FASB issued an accounting standards update that is aimed at addressing certain issues regarding classifications of certain cash receipt and cash payment on the statement of cash flows where diversity in practice was identified. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted. The Company will be required to apply the guidance retrospectively in the first interim and annual periods in which the guidance is adopted. The Company does not believe that the adoption of this accounting guidance will have a material impact on the Company’s consolidated financial statements and related disclosures. In October 2016, the FASB issued an accounting standards update that requires an entity to recognize the income tax consequences of intra-entity transfer of an asset other than inventory when the transfer occurs. The guidance is effective for the Company's interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted as of the beginning of an annual reporting period for which financial statements, interim or annual, have not been issued. The amendments will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In November 2016, the FASB issued an accounting standards update that will require entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, the Company will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The guidance is effective for the Company's interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted, including adoption in an interim period. The amendments will be applied using a retrospective transition method to each period presented. The Company will be required to apply the guidance retrospectively when adopted. The Company does not believe that the adoption of this accounting guidance will have a material impact on its consolidated financial statements and related disclosures. In January 2017, the FASB issued an accounting standards update that provides guidance to assist entities with evaluating when a set of transferred assets and activities is a business. Under the updated guidance, a set is not a business if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar assets. If the threshold is not met, the update requires that, to be a business, the set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. The definition of outputs was also aligned with ASC 606 by focusing on revenue-generating activities. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018, and prospectively applicable to any transactions occurring within the period of adoption. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued an accounting standards update that eliminates the requirement to calculate the implied fair value of goodwill. An entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020, and applied on a prospective basis. Early adoption is permitted for interim and annual goodwill impairment testing dates after January 1, 2017. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures.

Business Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2016
Business Acquisition
Business Acquisition	3. Business Acquisitions Acquisition of International Medication Systems (UK) Limited from UCB PHARMA GmbH In August 2016, the Company’s newly established UK subsidiary, AUK, acquired IMS UK, a UK-based subsidiary of UCB PHARMA GmbH, including its trademarks, assets related to the products, as well as marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities. The Company paid $7.7 million in cash as consideration for the transaction. The Company plans to transfer the manufacturing of the purchased products to its facilities in California. The transfer will require approval of the UK Medicines and Healthcare products Regulatory Agency and other related regulatory agencies before the products can be sold by the Company. The transaction is accounted for as a business combination in accordance with ASC 805. The fair values of the assets acquired and liabilities assumed include marketing authorizations of $9.2 million, manufacturing equipment of $0.1 million, and deferred tax liability of $1.6 million. The acquired marketing authorizations intangible assets are subject to a straight-line amortization over a useful life of approximately 10 years. Acquisition of fourteen injectable products from Hikma Pharmaceuticals PLC In March 2016, the Company acquired 14 abbreviated new drug applications, or ANDAs, representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC, or Hikma, for $4.0 million. The Company has concluded that this transaction will be accounted for as a business combination in accordance with ASC 805. The ANDAs are estimated to have a fair value of $4.0 million, which is subject to a straight-line amortization over a useful life of approximately 15 years. In February 2017, the Company sold these products to an unrelated party. (See note 18) Acquisition of Nanjing Letop Medical Technology Co. Ltd. In January 2016, the Company’s Chinese subsidiary, ANP, acquired Nanjing Letop Medical Technology Co. Ltd. for $1.7 million consisting of $0.8 million in cash and a deposit of $0.9 million that ANP had previously paid to Letop and which was effectively eliminated upon the consummation of the transaction. The Company accounted for this transaction as a business combination in accordance with ASC 805. The Company recognized $1.4 million of acquired assets, $0.1 million of assumed liabilities, and $0.4 million of goodwill. Letop had previously supplied ANP with intermediates used in making various active pharmaceutical ingredients. In March 2016, the acquired subsidiary was renamed Nanjing Letop Fine Chemistry Co., Ltd. Acquisition of Merck’s API Manufacturing Business On April 30, 2014, the Company completed the acquisition of the Merck Sharpe & Dohme’s API manufacturing business in Éragny-sur-Epte, France, or the Merck API Transaction, which manufactures porcine insulin API and recombinant human insulin API, or RHI API. The purchase price of the transaction totaled €24.8 million, or $34.4 million on April 30, 2014, subject to certain customary post‑closing adjustments and currency exchange rate fluctuations. The terms of the purchase include multiple payments over four years as follows (see Note 12): U.S. Euros Dollars (in thousands) At Closing, April 2014 € $ December 2014 December 2015 December 2016 December 2017 € $ In order to facilitate the acquisition, the Company established AFP in France. The Company is continuing the current site manufacturing activities, which consist of the manufacturing of porcine insulin API and RHI API. As part of the transaction, the Company has entered into various additional agreements, including various supply agreements, as well as the assignment and/or licensing of patents under which Merck was operating at this facility. In addition, certain existing customer agreements have been assigned to AFP. Currently, the Company is in the process of transferring the manufacturing of starting material for RHI API from Merck to AFP. This process will require capital expenditures at AFP and is expected to take two or more years to complete. The transaction is accounted for as a business combination in accordance with ASC 805. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date: Fair Value U.S. Euros Dollars (in thousands) Inventory € $ Real property Machinery and equipment Intangibles Goodwill Total assets acquired € $ Accrued liabilities € $ Deferred tax liabilities Total liabilities assumed Total fair value of consideration transferred € $ The operations of the acquired business have been included in the Company’s consolidated financial statements commencing on the acquisition date. The results of operations for this acquisition have not been separately presented because this acquisition is not material to the Company’s consolidated results of operations. The following unaudited pro forma financial information for the years ended December 31, 2014 and 2013 gives effect to the transaction as if it had occurred on January 1, 2013. Such unaudited pro forma information is based on historical financial information prior to the transaction as well as actual results subsequent to the acquisition with respect to the transaction and does not reflect estimated operational and administrative cost savings, or synergies, for periods prior to the transaction, that management of the combined company estimates may be achieved as a result of the transaction. The unaudited pro forma information primarily reflects the additional depreciation related to the fair value adjustment to property, plant and equipment acquired, valuation step up related to the fair value of inventory and additional interest expense associated with the financing obtained by the Company in connection with the acquisition. Year Ended December 31, 2014 2013 (in thousands, except per share data) Net revenues $ $ Net loss Diluted net loss per share $ $

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2016
Revenue Recognition
Revenue Recognition	4. Revenue Recognition Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, after the customer has accepted test samples of the products to be shipped. On June 30, 2016, the Company and Actavis amended the distribution agreement, which terminated the agreement in December 2016. Profit-sharing revenue under this agreement was recognized at the time Actavis sold the products to its customers. The Company does not recognize product revenue unless the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) transfer of title has occurred, (iii) the price to the customer is fixed or determinable, and (iv) collection is reasonably assured. Furthermore, the Company does not recognize revenue until all customer acceptance requirements have been met. The Company estimates and records reductions to revenue for discounts, product returns, and pricing adjustments, such as wholesaler chargebacks, in the same period that the related revenue is recorded. The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple deliverables. Provision for Wholesaler Chargebacks The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing. The provision for chargebacks is reflected in net revenues and a reduction to accounts receivable. The following table is an analysis of the chargeback provision: Year Ended December 31, 2016 2015 (in thousands) Beginning balance $ $ Provision related to sales made in the current period Credits issued to third parties Ending balance $ $ Changes in chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by the wholesalers, and on the wholesaler’s customer mix. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and makes adjustments when it believes that the actual chargebacks may differ from the estimates. The settlement of chargebacks generally occurs within 30 days after the sale to wholesalers. Accrual for Product Returns The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, products sold to Actavis were and API product sales are non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for estimated returns. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate. If the available information is not sufficient to estimate a reasonable product return accrual, revenues from the sales of the new product would not be recognized until the product is consumed by the end customer or rights of return granted under the return policy have expired. As of December 31, 2016, sales of approximately $0.5 million for one of the Company’s products were not recognized in revenues, due to insufficient information available to estimate a reasonable product return accrual. The provision for product returns is reflected in net revenues. The following table is an analysis of product return liability: Year Ended December 31, 2016 2015 (in thousands) Beginning balance $ $ Provision for product returns Credits issued to third parties Ending balance $ $ For the years ended December 31, 2016 and 2015 , the Company’s aggregate product return rate was 1 .1% and 1.1% of qualified sales, respectively.

Income (Loss) per Share

Income (Loss) per Share	12 Months Ended
	Dec. 31, 2016
Income (Loss) per Share
Income (Loss) per Share	5. Income (Loss) per Share Basic income (loss) per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted income per share gives effect to all potential dilutive shares outstanding during the period, such as stock options, nonvested deferred stock units and restricted stock units (collectively referred to herein as “RSUs”), and shares issuable under the Company’s Employee Stock Purchase Plan, or the ESPP. For the year ended December 31, 2016, options to purchase 2,379,984 shares of stock with a weighted-average exercise price of $22.46 per share, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive. As the Company reported a net loss for the years ended December 31, 2015 and 2014, the diluted net loss per share, as reported, equals the basic net loss per share since the effect of the assumed exercise of stock options, vesting of nonvested RSUs, and issuance of common shares under the Company’s ESPP are anti-dilutive. Total stock options, nonvested RSUs, and shares issuable under the Company’s ESPP excluded from the year ended December 31, 2015 net loss per share were 12,240,467 stock options; 866,540 nonvested RSUs, and 61,766 shares issuable under the ESPP. Total stock options and nonvested RSUs excluded from the year ended December 31, 2014 net loss per share were 11,371,891 stock options and 503,010 nonvested RSUs. The following table provides the calculation of basic and diluted net income (loss) per share for each of the periods presented: Year Ended December 31, 2016 2015 2014 (in thousands, except per share data) Basic and dilutive numerator: Net income (loss) $ $ $ Denominator: Weighted-average shares outstanding — basic Net effect of dilutive securities: Incremental shares from equity awards — — Weighted-average shares outstanding — diluted Net income (loss) per share — basic $ $ $ Net income (loss) per share — diluted $ $ $

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2016
Segment Reporting
Segment Reporting	6. Segment Reporting The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has established two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments: · Finished pharmaceutical products · Active pharmaceutical ingredients, or API The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn ® , Amphadase ® , naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Selected financial information by reporting segment is presented below: Year Ended December 31, 2016 2015 2014 (in thousands) Net revenues: Finished pharmaceutical products $ $ $ API Total net revenues Gross profit: Finished pharmaceutical products API Total gross profit Operating expenses Income (loss) from operations Non-operating expenses Income (loss) before income taxes $ $ $ The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets. The amount of net revenues in the finished pharmaceutical products segment is presented below: Year Ended December 31, 2016 2015 2014 (in thousands) Finished pharmaceutical products net revenues: Enoxaparin $ $ $ Naloxone Lidocaine Phytonadione Epinephrine Other finished pharmaceutical products Total finished pharmaceutical products net revenues $ $ $ Net revenues and carrying values of long-lived assets of enterprises by geographic regions are as follows: Net Revenue Long-Lived Assets Year Ended December 31, December 31, 2016 2015 2014 2016 2015 (in thousands) United States $ $ $ $ $ China — — — France United Kingdom — — — — Total $ $ $ $ $

Customer and Supplier Concentra

Customer and Supplier Concentration	12 Months Ended
	Dec. 31, 2016
Customer and Supplier Concentration
Customer and Supplier Concentration	7. Customer and Supplier Concentration Customer Concentrations Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc. or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Actavis had exclusive marketing rights of the Company’s enoxaparin product to the U.S. retail pharmacy market (see Note 16). MannKind Corporation began buying RHI API from the Company in December 2014. The Company considers these five customers to be its major customers, as each individually and these customers collectively, represented a significant percentage of the Company’s net revenue for the years ended December 31, 2016, 2015, and 2014, and accounts receivable as of December 31, 2016 and 2015. The following table provides accounts receivable and net revenues information for these major customers: % of Total Accounts % of Net Receivable Revenue December 31, December 31, Year Ended December 31, 2016 2015 2016 2015 2014 Actavis (1) % % % % % AmerisourceBergen % % % % % Cardinal Health % % % % % MannKind Corporation % % % % % McKesson % % % % % (1) The Agreement with Actavis was terminated in December 2016. Supplier Concentrations The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent U.S. Food and Drug Administration, or FDA, requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Measurements
Fair Value Measurements	8. Fair Value Measurements The accounting standards of the FASB, define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below: · Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities; · Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and · Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances. The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company classifies its cash equivalents and restricted short-term investments as Level 1 assets, as they are valued on a recurring basis using quoted market prices with no valuation adjustments applied. The Company does not hold any Level 3 instruments that are measured for fair value on a recurring basis. The fair values of the Company’s financial assets and liabilities measured on a recurring basis, as of December 31, 2016 and 2015, are as follows: Quoted Prices in Active Markets Significant Other Significant Other for Identical Observable Unobservable Assets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2016 $ $ $ — $ — Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2015 $ $ $ — $ — The fair value of the Company’s cash equivalents includes money market accounts, money market funds, Money Market Insured Deposit Account Service and Insured Cash Sweep accounts. Restricted short-term investments consist of certificate of deposit accounts that expire within 12 months for which market prices are readily available. The restrictions placed on the certificate of deposit accounts have a negligible effect on the fair value of these financial assets; these funds are restricted to meet the Company’s obligation for workers’ compensation claims. Short-term investments primarily consist of held-to-maturity municipal bonds with original maturities greater than three months. The municipal bonds are carried at amortized cost in the Company’s consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The Company does not intend to and will not be required to sell the investments before recovery of their amortized cost basis. The Company adopted the required fair value measurements and disclosures provisions related to nonfinancial assets and liabilities. These assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of December 31, 2016 and 2015, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification: Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Cortrosyn ® product rights 12 $ $ $ IMS (UK) international product rights (1) 10 Acquired ANDAs (2) 15 Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill - Finished pharmaceutical products * — Subtotal * — As of December 31, 2016 * $ $ $ Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Cortrosyn ® product rights 12 $ $ $ Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill - Finished pharmaceutical products * — Subtotal * — As of December 31, 2015 * $ $ $ * Intangible assets with indefinite lives have an indeterminable average life. (1) In August 2016, the Company acquired International Medication Systems (UK) Limited from UCB PHARMA GmbH for $7.7 million. The fair value of the marketing authorization was $9.2 million as of the acquisition date (see Note 3). (2) In March 2016, the Company acquired 14 ANDAs representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million (see Note 3). In February 2017, the Company sold the 14 ANDAs to an unrelated party purchaser for $6.4 million (see note 18). Goodwill The changes in the carrying amounts of goodwill were as follows: December 31, 2016 2015 (in thousands) Beginning balance $ $ Goodwill related to acquisition of business — Currency translation and other adjustments Ending balance $ $ Primatene ® Trademark In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene ® Mist, an over-the-counter bronchodilator product, which are recorded at the allocated fair value of $29.2 million, which is its carrying value as of December 31, 2016. The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors. As a result of environmental concerns about Chlorofluorocarbons, or CFCs, the FDA issued a final ruling on January 16, 2009 that required the CFC formulation of its Primatene ® Mist product to be phased out by December 31, 2011. The former formulation of Primatene ® Mist contained CFCs as a propellant; however, the Company intends to use the trademark for a future version of Primatene ® that utilizes hydrofluoroalkane, or HFA, as a propellant. In 2013, the Company filed a new drug application, or NDA, for Primatene ® Mist and received a Prescription Drug User Fee Act date set for May 2014. In May 2014, the Company received a complete response letter, or CRL, from the FDA, which requires additional non-clinical information, label revisions and follow-up studies (label comprehension, behavioral/human factors and actual use) to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting. The Company met with the FDA in October 2014 to discuss preliminary data results and to clarify the FDA requirements for further studies. The Company received further advice regarding its ongoing studies from the FDA in January 2016 and subsequently completed the human factor studies accordingly. The Company submitted a responsive NDA amendment in June 2016 and received another CRL from the FDA in December 2016, which requires additional packaging and label revisions and follow-up studies to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting . The Company intends to continue to work with the FDA during the post-action phase to address their concerns in the CRL and bring Primatene ® Mist back to the over-the-counter market. However, there can be no guarantee that any future amendment to the Company’s NDA will result in timely approval of Primatene ® Mist or approval at all. Based on the Company’s filed version of Primatene ® Mist, the long history of the Primatene trademark (marketed since 1963), the Company’s perpetual rights to the trademark, the nature of the CRL received in December 2016, the plan that the HFA version will be marketed under the same trademark if approved by the FDA, and other factors previously considered, the trademark continues to have an indefinite useful life, and an impairment charge is not required based on the Company’s qualitative assessment as of December 31, 2016. Amortization Included in cost of revenues for the years ended December 31, 2016, 2015 and 2014 is product rights amortization expense of $2.4 million, $1.8 million, and $1.8 million, respectively, primarily related to Cortrosyn ® . As of December 31, 2016, the expected amortization expense for all amortizable intangible assets during the next five fiscal years ended December 31 and thereafter is as follows: (in thousands) 2017 $ 2018 2019 2020 2021 Thereafter Total amortizable intangible assets Indefinite-lived intangibles Total intangibles (net of accumulated amortization) $

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventories
Inventories	10. Inventories Inventories consist of the following: December 31, 2016 2015 (in thousands) Raw materials and supplies $ $ Work in process Finished goods Total inventories $ $

Property, Plant, and Equipment

Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant, and Equipment
Property, Plant, and Equipment	11. Property, Plant, and Equipment Property, plant, and equipment consist of the following: December 31, 2016 2015 (in thousands) Buildings $ $ Leasehold improvements Land Machinery and equipment Furniture, fixtures, and automobiles Construction in progress Total property, plant, and equipment Less accumulated depreciation Total property, plant, and equipment, net $ $ The Company incurred depreciation expense of $12.0 million, $11.3 million, and $12.5 million for the years ended December 31, 2016, 2015, and 2014, respectively. Interest expense capitalized was approximately $0.8 million, $1.1 million, and $1.2 million, for the years ended December 31, 2016, 2015, and 2014, respectively. The interest expense capitalized is primarily related to certain foreign construction projects during the year. As of December 31, 2016 and 2015, the Company had $2.6 million and $2.9 million, respectively, in capitalized manufacturing equipment that is intended to be used specifically for the manufacture of Primatene ® Mist. The Company will continue to monitor developments with the FDA as it relates to its Primatene ® indefinite lived intangible assets in determining if there is an impairment of these related fixed assets (see Note 9).

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt
Debt	12. Debt Debt consists of the following: December 31, 2016 2015 (in thousands) Loans with East West Bank Mortgage payable matured January 2016 $ — $ Mortgage payable matured September 2016 — Equipment loan due April 2017 Line of credit facility due September 2017 — — Equipment loan due January 2019 Mortgage payable due February 2021 — Equipment credit line due September 2021 — Mortgage payable due October 2026 — Loans with Cathay Bank Line of credit facility due May 2018 — — Acquisition loan due April 2019 Mortgage payable due April 2021 Loans with Seine-Normandie Water Agency French government loan 1 due March 2018 French government loan 2 due June 2020 French government loan 3 due July 2021 Payment Obligation to Merck Equipment under Capital Leases Total debt and capital leases Less current portion of long-term debt and capital leases Long-term debt and capital leases, net of current portion $ $ Loans with East West Bank Equipment Loan—Due April 2017 In March 2012, the Company entered into an $8.0 million revolving credit facility. In March 2013, the Company converted the outstanding principal balance of $4.9 million into an equipment loan, which matures in April 2017. Borrowings under the facility are secured by equipment. Borrowings under the facility bear a variable interest rate at the prime rate as published by The Wall Street Journal plus 0.25%, with a minimum interest rate of 3.50%. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Line of Credit Facility—Due September 2017 In March 2012, the Company entered into a $10.0 million line of credit facility. Borrowings under the facility are secured by inventory and accounts receivable. Borrowings under the facility bear a variable interest rate at the prime rate as published by The Wall Street Journal . This facility matured in March 2016. In March 2016, the Company amended the facility to increase the line of credit to $15.0 million and extended the maturity date to September 2017. As of December 31, 2016, the Company did not have any amounts outstanding under this facility. Equipment Loan—Due January 2019 In July 2013, the Company entered into an $8.0 million line of credit facility. Borrowings under the facility were secured by equipment. The facility bore a variable interest rate at the prime rate as published in The Wall Street Journal plus 0.25% and was to mature in January 2019. In January 2015, the Company drew down $6.2 million from the line of credit facility. Subsequently, the facility was converted into an equipment loan with an outstanding principal balance of $6.2 million and a maturity date of January 2019. Borrowings under the facility are secured by equipment purchased with the debt proceeds. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. The Company entered into a fixed interest rate swap contract on this facility to exchange the variable interest rate for a fixed interest rate of 4.48% over the life of the facility without the exchange of the underlying notional debt amount. The interest rate swap contract does not qualify for hedge accounting, and is recorded at fair value for an immaterial amount based on Level 2 inputs. Mortgage Payable—Due February 2021 In December 2010, the Company refinanced an existing mortgage term loan, which had an outstanding principal balance of $4.5 million at December 31, 2010. The loan was payable in monthly installments with a final balloon payment of $3.8 million. The loan was secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex, as well as one of its buildings at its Chino, California, complex. The loan had a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%, and matured in January 2016. The Company refinanced the mortgage term loan in January 2016, which had an outstanding principal balance of $3.7 million at December 31, 2015, and a maturity date of February 2021. The refinanced loan is payable in monthly installments with a final balloon payment of $3.3 million. The refinanced loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The refinanced loan has a variable interest rate at the prime rate as published by The Wall Street Journal . As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. The Company entered into a fixed interest rate swap contract on this loan to exchange the variable interest rate for a fixed interest rate of 4.39% over the life of the loan without the exchange of the underlying notional debt amount. The interest rate swap contract does not qualify for hedge accounting, and is recorded at fair value for an immaterial amount based on Level 2 inputs. Equipment Credit Line–Due September 2021 In March 2016, the Company entered into a $5.0 million equipment credit line with an 18-month draw down period and interest payments due monthly through September 2017 at the prime rate as published by The Wall Street Journal . After the draw down period, the outstanding principal balance converts into a 48-month loan with principal and interest payments due monthly. Borrowings under the facility are secured by equipment, and bear a variable interest rate at the prime rate as published by The Wall Street Journal . This facility matures in September 2021. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. As of December 31, 2016, the Company has drawn $2.9 million from the equipment line of credit. Mortgage Payable—Due October 2026 In September 2006, the Company entered into a mortgage term loan in the principal amount of $2.8 million, which matured in September 2016. The loan was payable in monthly installments with a final balloon payment of $2.2 million plus interest. The loan was secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The variable interest rate was equal to the three-month LIBOR plus 2.50%. The Company refinanced the mortgage term loan in September 2016, which increased the principal amount to $3.6 million and extended the maturity date to October 2026. The refinanced loan is payable in monthly installments with a final balloon payment of $2.9 million. The refinanced loan has a variable interest rate at the one-month LIBOR rate plus 2.75%. Subsequently, the Company entered into a fixed interest rate swap contract on this loan to exchange the variable interest rate for a fixed interest rate of 4.15% until October 2021 without the exchange of the underlying notional debt amount. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. The interest rate swap contract does not qualify for hedge accounting, and is recorded at fair value for an immaterial amount based on Level 2 inputs. Loans with Cathay Bank Line of Credit Facility—Due May 2018 In April 2012, the Company entered into a $20.0 million revolving line of credit facility. Borrowings under the facility are secured by inventory, accounts receivable, and intangibles held by the Company. The facility bears a variable interest rate at the prime rate as published by The Wall Street Journal with a minimum interest rate of 4.00%. This revolving line of credit was to mature in May 2016. In June 2016, the Company modified the facility to extend the maturity date to May 2018. As of December 31, 2016, the Company did not have any amounts outstanding under this facility. Acquisition Loan with Cathay Bank—Due April 2019 On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan with Cathay Bank as lender. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Beginning on June 1, 2014, and through the maturity date April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120-month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days. Mortgage Payable—Due April 2021 In March 2007, the Company entered into a mortgage term loan in the principal amount of $5.3 million, which matured in March 2014. In April 2014, the Company refinanced the mortgage term loan, which had a principal balance outstanding of $4.6 million. The loan is payable in monthly installments with a final balloon payment of $3.9 million. The loan is secured by the building at the Company’s Canton, Massachusetts location and bears interest at a fixed rate of 5.42% and matures in April 2021. As of December 31, 2016, the fair value of the loan approximates its book value. The interest rate used in the fair value estimation was determined to be a Level 2 input. Loans with Seine-Normandie Water Agency In January 2015, the Company entered into three French government loans with the Seine-Normandie water agency in the aggregate amount of €0.6 million, or $0.7 million, subject to currency exchange fluctuations. The life of the loans range between three to six years, and includes annual equal payments and bears no interest over the life of the loans. As of December 31, 2016, the payment obligation had an aggregate book value of €0.4 million, or $0.4 million, subject to currency exchange rate fluctuations, which approximates fair value. The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Such interest rate is deemed to be a Level 2 input for measuring fair value. Payment Obligation to Merck Merck—Due December 2017 On April 30, 2014, in conjunction with the Merck API Transaction, the Company entered into a commitment obligation with Merck, in the principal amount of €11.6 million, or $16.0 million, subject to currency exchange rate fluctuations. The terms of the purchase price include annual payments over four years and bear a fixed interest rate of 3.00%. The final payment to Merck relating to this obligation is due December 2017. In December 2016 and 2015, the Company made a principal payment of €3.2 million, or $3.4 million and €3.2 million, or $3.5 million, respectively. As of December 31, 2016, the payment obligation had a book value of €0.5 million, or $0.5 million, which approximates fair value. The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by The Wall Street Journal , with a minimum interest rate of 4.00%. Such interest rate is deemed to be a Level 2 input for measuring fair value. Covenants At December 31, 2016 and 2015, the Company was in compliance with its debt covenants, which include a minimum current ratio, minimum debt service coverage, minimum tangible net worth, and maximum debt-to-effective-tangible-net-worth ratio, computed on a consolidated basis. Equipment under Capital Leases The Company entered into leases for certain equipment under capital leasing arrangements, which will expire at various times through 2021. The cost of equipment under capital leases was $2.0 million and $1.5 million at December 31, 2016 and 2015, respectively. The accumulated depreciation of equipment under capital leases was $0.2 million and $0.7 million at December 31, 2016 and 2015, respectively. Depreciation of assets recorded under capital leases is included in depreciation expense in the accompanying consolidated financial statements. Long-Term Debt Maturities As of December 31, 2016, the principal amounts of long-term debt maturities during each of the next five fiscal years ending December 31 are as follows: Capital Debt Leases Total (in thousands) 2017 $ $ 2018 2019 2020 2021 Thereafter — $ $ $

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes
Income Taxes	13. Income Taxes The Company’s income (loss) before income taxes generated from its United States and foreign operations were: Year Ended December 31, 2016 2015 2014 (in thousands) Income (loss) before income taxes: United States $ $ $ Foreign Total income (loss) before taxes $ $ $ The Company’s provision (benefit) for income taxes consisted of the following: Year Ended December 31, 2016 2015 2014 (in thousands) Current provision (benefit): Federal $ $ $ State Foreign Total current provision Deferred provision (benefit): Federal State Foreign Total deferred benefit Total provision (benefit) for income taxes $ $ $ A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2016 2015 2014 Statutory federal income tax (benefit) % % % State tax expense, net of federal tax benefit Foreign tax rate differences Foreign valuation allowance — Qualified production activities deduction — — Research and development credits Share-based compensation Other — Effective tax rate (benefit) % % % Deferred Tax Assets and Liabilities Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards, and the tax effects of net operating loss carryforwards. The significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2016 2015 (in thousands) Deferred tax assets: Net operating loss carryforward $ $ State income taxes Inventory capitalization and reserve Deferred revenue — Accrued payroll and benefits Share-based compensation Research and development credits Alternative minimum tax Accrued professional fees Product return allowance Accrued chargebacks Bad debt reserve Intangibles Accrued for workers’ compensation insurance Total deferred tax assets Deferred tax liabilities: Depreciation/amortization Intangibles Federal impact of state deferred taxes Other Total deferred tax liabilities Valuation allowance Net deferred tax assets $ $ Net Operating Loss Carryforwards and Tax Credits At December 31, 2016, the Company had no material U.S. federal, California, or other State net operating loss, or NOL carryforwards. The Company had foreign NOL carryforwards of approximately $16.7 million which can be used annually with certain limitations and have an indefinite carryforward period. At December 31, 2016, the Company had federal and California research and development tax credit carryforwards of approximately $2.6 million and $11.7 million, respectively. The federal research and development tax credit begins to expire in 2035. The California research and development tax credit has an indefinite carryforward period. The Company also had a U.S. federal alternative minimum tax credit carryforward of $0.5 million which can be used to offset future regular tax to the extent of the current AMT; the credit has an indefinite carryforward period. The utilization of NOL and credit carryforwards and other tax attributes could be subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (the “Code”), whereby they could be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period, as defined in the Code. Valuation Allowance In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. Ultimately, the realization of deferred tax assets depends on the existence of future taxable income. M anagement considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income. The Company recorded a valuation allowance against a deferred tax asset with the AFP purchase accounting in 2014 of €3.2 million, or $4.4 million, subject to currency exchange rate fluctuations, with an offsetting increase to goodwill. In March 2015, the Company reversed the €3.2 million, or $3.3 million, subject to currency exchange rate fluctuations, deferred tax valuation allowance in conjunction with the transfer of AFPs intangible assets from France to the United States. In addition, in 2015, the Company assessed the realizability of the deferred tax assets of AFP and determined that it was not more likely than not that the net deferred tax assets of AFP would be realized. Therefore, the Company established a full valuation allowance of $0.9 million as of December 31, 2015. The Company has discontinued recognizing AFP income tax benefits until it is determined that it is more likely than not that AFP will generate sufficient taxable income to realize its deferred income tax assets. As of December 31, 2016, the Company had a full valuation allowance against the deferred tax assets of AFP, which totaled $3.0 million. Undistributed Losses from Foreign Operations As of December 31, 2016 and 2015, deferred income taxes have not been provided on the accumulated undistributed losses of the Company’s foreign subsidiaries of approximately $14.9 million and $7.1 million, respectively. It is the Company’s plan not to repatriate future foreign earnings to the U.S. Uncertain Income Tax Positions A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows: December 31, 2016 2015 2014 (in thousands) Balance at the beginning of the year $ $ $ Additions based on tax positions related to prior years — — Additions based on tax positions related to the current year Deductions based on statute of limitations — — Balance at the end of the year $ $ $ Included in the balance of unrecognized tax benefits as of December 31, 2016, was $5.9 million that represents the portion that would impact the effective income tax rate if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefit as of December 31, 2016, will decline by $1.9 million in the next 12 months as a result of the expected resolution of a current U.S. state audit. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax provision. For the years ended December 31, 2016 and 2015, the Company recognized accrued interest of approximately $0.3 million and $0.1 million, respectively, related to its uncertain tax position. The Company and/or one or more of its subsidiaries filed income tax returns in the U.S. federal jurisdiction and various U.S. states and foreign jurisdictions. As of December 31, 2016, the Company is not subject to U.S. federal, state, and foreign income tax examinations for years before 2007. In August 2011, the California Franchise Tax Board commenced an audit of the Company’s 2007, 2008, and 2009 tax returns; this audit is currently ongoing. The Company is subject to income tax audit by tax authorities for tax years 2013, 2014 and 2015 for federal and 2007 to 2015 for states.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity
Stockholders' Equity	14. Stockholders' Equity Common and Preferred Stock In June 2014, the Company completed an initial public offering in which the Company sold 5,840,000 shares of its common stock, which included 1,200,000 shares of the Company’s common stock pursuant to the underwriters’ exercise of their over-allotment option, at a price to the public of $7.00 per share, resulting in gross proceeds of $40.9 million. In connection with the offering, the Company paid $6.2 million in underwriting discounts, commissions, and offering costs, resulting in net proceeds of $34.7 million. The Company’s Certificate of Incorporation, as amended and restated in June 2014 in connection with the closing of its initial public offering, authorizes the Company to issue 300,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.0001 par value per share. As of December 31, 2016 and 2015, there were no shares of preferred stock issued or outstanding. Equity Plans As of December 31, 2016, the Company has two equity plans: the 2015 Equity Incentive Award Plan, or 2015 Plan, and the 2014 Employee Stock Purchase Plan or ESPP. Prior to the adoption of these plans, the Company granted options pursuant to the Amended and Restated 2005 Equity Incentive Award Plan and the 2002 Amended and Restated Stock Option/Stock Issuance Plan. Upon termination of the predecessor plans, the shares available for grant at the time of termination, and shares subsequently returned to the plans upon forfeiture or option termination, were transferred to the successor plan in effect at the time of share return. The Company issues new shares of common stock upon exercise of stock options, vesting of restricted stock units, or RSU, and settlement of ESPP, with the exception of the awards granted to employees at AFP, which are settled through re-issuance of the Company’s treasury shares. The 2015 Equity Incentive Plan In March 2015, the Board of Directors adopted the Company’s 2015 Equity Incentive Plan, or the 2015 Plan, which was approved by the Company’s stockholders in May 2015 and is set to expire in March 2025. The 2015 Plan is designed to meet the needs of a publicly traded company, including the requirements for granting “performance based compensation” under Section 162(m) of the Internal Revenue Code. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, performance shares, and other stock or cash awards to employees of the Company and its subsidiaries, members of the Board of Directors and consultants. The Company initially reserved 5,000,000 shares of common stock for issuance under the 2015 Plan. This number will be increased by the number of shares available for issuance under the Company’s prior equity incentive plans or arrangements that are not subject to options or other awards, plus the number of shares of common stock related to options or other awards granted under the Company’s prior equity incentive plans or arrangements that are repurchased, forfeited, expired, or cancelled on or after the effective date of the 2015 Plan. The 2015 Plan also contains an “evergreen provision” that allows for an annual increase in the number of shares available for issuance on January 1 of each year during the 10 year term of the 2015 Plan, beginning January 1, 2016. The annual increase in the number of shares shall be the lessor of (i) 3,000,000 shares, (ii) two and one-half percent ( 2.5% ) of the outstanding shares on the last day of the immediately preceding fiscal year, or (iii) such number of shares as determined by the Board of Directors. As of the effective date, there were 5,300,296 shares available for grant under the 2015 Plan. As of December 31, 2016, the Company reserved an aggregate of 4,164,625 shares of common stock for future issuance under the 2015 Plan. In January 2017, an additional 1,156,216 shares were reserved under the 2015 Plan pursuant to the evergreen provision. Amended and Restated 2005 Equity Incentive Award Plan The Amended and Restated 2005 Equity Incentive Award Plan, or 2005 Plan provided for the grant of incentive stock options, or ISOs, nonqualified stock options, or NQSOs, restricted stock awards, restricted stock unit awards, stock appreciation rights, or SARs, dividend equivalents and stock payments to the Company’s employees, members of the Board of Directors and consultants. Stock options under the 2005 Plan were granted with a term of up to ten years and at prices no less than the fair market value of the Company’s common stock on the date of grant. To date, stock options granted to existing employees generally vest over three to five years and stock options granted to new employees vest over four years. As of March 2015, consequent to the 2015 Plan becoming effective, awards were no longer being made under the 2005 Plan. 2014 Employee Stock Purchase Plan In June 2014, the Company adopted the ESPP in connection with its initial public offering. A total of 2,000,000 shares of common stock are reserved for issuance under this plan. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal 85% of the lower of the fair market value of the common stock at the beginning of an offering period or on the date of purchase. As of December 31, 2016, the Company has issued 248,587 shares of common stock under the ESPP and 1,751,413 shares of its common stock remained available for issuance under the ESPP. For the year ended December 31, 2016 and 2015, the Company recorded ESPP expense of $0.5 million and $0.4 million, respectively. Share Buyback Program On November 6, 2014, the Company’s Board of Directors authorized a $10.0 million share buyback program, which was completed in December 2015. On November 10, 2015, the Company’s Board of Directors authorized an additional $10.0 million to the Company’s share buyback program. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs. On November 7, 2016, the Company’s Board of Directors authorized an increase of $20.0 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. Purchases are being made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These repurchased shares are accounted for under the cost method and are included as a component of treasury stock in the Company’s Consolidated Balance Sheets. Pursuant to the Company’s share repurchase program, the Company purchased 759,067 and 735,679 shares of its common stock during the years ended December 31, 2016 and 2015, totaling $9.9 million and $9.9 million, respectively. Share-Based Award Activity and Balances The Company accounts for share‑based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share‑based payment awards made to employees, directors, and nonemployees. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. Non‑vested stock options held by non-employees are revalued using the Company’s estimate of fair value at each balance sheet date. The portion that is ultimately expected to vest is amortized and recognized in the compensation expenses on a straight-line basis over the requisite service period, generally from the grant date to the vesting date. Options issued under the Company’s 2015 Plan and 2005 Plan, are granted at exercise prices equal to or greater than the fair value of the underlying common shares on the date of grant and vest based on continuous service. There have been no awards with performance conditions and no awards with market conditions. The options have a contractual term of five to ten years and generally vest over a three- to five‑year period. The Black‑Scholes option pricing model has various inputs such as the common share price on the date of grant, exercise price, the risk‑free interest rate, volatility, expected life and dividend yield, all of which are estimates. The Company records share‑based compensation expense net of expected forfeitures. The change of any of these inputs could significantly impact the determination of the fair value of the Company’s options as well as significantly impact its results of operations. The significant assumptions used in the Black-Scholes option-pricing are as follows: · Determining Fair Value of the underlying common stock. For options and ESPP awards granted after the completion of the Company’s initial public offering, the fair value for its underlying common stock is determined using the closing price on the date of grant as reported on the NASDAQ Global Select Market. Since the Company’s common stock was not traded in a public stock market exchange prior to June 25, 2014, prior to such date the Board of Directors considered numerous factors including recent cash sales of the Company’s common stock to third-party investors, new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company’s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses and the guideline company method using revenue and earnings multiples for comparable publicly traded companies, and a calculation of total option proceeds, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company’s initial public offering, the Board of Directors determined the Company’s common stock fair market value on a quarterly basis and in some cases more frequently when appropriate. · Expected Volatility. The Company has limited data regarding company‑specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average of the historical volatilities of peer group companies from publicly available data for sequential periods approximately equal to the expected terms of its option grants. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities. · Expected Term. The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience for employee exercise and post-vesting employment termination behavior after its common stock has been publicly traded. The expected term of “plain vanilla” options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted‑average expected term of the Company’s options is approximately five years. · Risk‑Free Rate. The risk‑free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero‑coupon issues with a term approximately equal to the expected life of the option being valued. · Dividends. The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero. The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual experience differs from those estimates. For the years ended December 31, 2016, 2015 and 2014, the Company estimated an average overall forfeiture rate of 7%, 8%, and 8%, respectively, based on historical experience. Forfeiture rates are separately estimated for its (1) directors and officers, (2) management personnel and (3) other employees. Share‑based compensation is recorded net of expected forfeitures. The Company periodically assesses the forfeiture rate and the amount of expense recognized based on estimated historical forfeitures as compared to actual forfeitures. Changes in estimates are recorded in the period they are identified. Tax benefits resulting from tax deductions in excess of the share‑based compensation cost recognized (excess tax benefits) are recorded in the statements of cash flows as financing activities. The weighted-averages for key assumptions used in determining the fair value of options granted during the years ended December 31, 2016, 2015, and 2014 are as follows: Year Ended December 31, 2016 2015 2014 Average volatility % % % Risk-free interest rate % % % Weighted-average expected life in years Dividend yield rate — % — % — % Stock Options A summary of option activity under all plans for the year ended December 31, 2016, is presented below: Weighted-Average Weighted-Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term (Years) Value (1) (in thousands) Outstanding as of December 31, 2015 $ Options granted Options exercised Options cancelled Options expired Outstanding as of December 31, 2016 $ $ Exercisable as of December 31, 2016 $ $ (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the Company’s common stock for those awards that have an exercise price below the estimated fair value at December 31, 2016. During the years ended December 31, 2016, 2015, and 2014, the Company recorded expense of $8.0 million, $7.9 million, and $6.7 million, respectively, related to stock options granted to employees under all plans, and expenses of $0.7 million, $0.5 million, and $0.6 million, respectively, related to stock options granted to the Board of Directors under all plans. Information relating to option grants and exercises is as follows: Year Ended December 31, 2016 2015 2014 (in thousands, except per share data) Weighted-average grant date fair value $ $ $ Intrinsic value of options exercised Cash received Total fair value of the options vested during the year A summary of the status of the Company’s nonvested options as of December 31, 2016, and changes during the year ended December 31, 2016, are presented below: Weighted-Average Grant Date Options Fair Value Nonvested as of December 31, 2015 $ Options granted Options vested Options forfeited Nonvested as of December 31, 2016 As of December 31, 2016, there was $10.9 million of total unrecognized compensation cost, net of forfeitures, related to nonvested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.1 years and will be adjusted for future changes in estimated forfeitures. Deferred Stock Units/Restricted Stock Units Beginning in 2007, the Company granted deferred stock units, or DSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years, and commencing in 2015, such equity was issued as restricted stock units, or RSUs (such RSUs and DSUs are collectively referred to herein as RSUs). The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period, using the straight-line method. During the years ended December 31, 2016, 2015, and 2014, the Company recorded expenses of $5.2 million, $3.4 million, and $1.6 million, respectively, related to RSU awards granted to employees under all plans, and expenses of $0.7 million, $0.5 million, and $0.4 million, respectively, related to RSU awards granted to the Board of Directors. As of December 31, 2016, there was $10.1 million of total unrecognized compensation cost, net of forfeitures, related to nonvested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.3 years and will be adjusted for future changes in estimated forfeitures. Information relating to RSU grants and deliveries is as follows: Total Fair Market Value of RSUs Issued Total RSUs as Issued Compensation (1) (in thousands) RSUs outstanding at December 31, 2015 RSUs granted $ RSUs forfeited Common stock delivered RSUs surrendered for taxes RSUs outstanding at December 31, 2016 (1) The total FMV is derived from the number of RSUs granted times the current stock price on the date of grant. Equity Awards to Consultants The Company has entered into various consulting agreements with Company stockholders and third-party consultants. Consulting expenses are accrued as services are rendered. Consulting services are paid in cash and/or in common stock or stock options. Share-based compensation expense is recorded over the service period based on the estimated fair market value of the equity award at the date services are performed or upon completion of all services under the agreement. During the year ended December 31, 2016, the Company recorded $0.1 million in share-based compensation related to the issuance of equity awards for services rendered by consultants. During the year ended December 31, 2015, the Company recorded $0.2 million in share-based compensation related to the issuance of equity awards for service rendered by consultants. During the year ended December 31, 2014, the Company recorded an immaterial amount of share-based compensation related to the issuance of equity awards for services rendered by consultants. The Company recorded share-based compensation expense under all plans and is included in the Company’s consolidated statement of operations as follows: Year Ended December 31, 2016 2015 2014 (in thousands) Cost of revenues $ $ $ Operating expenses: Selling, distribution, and marketing General and administrative Research and development Total share-based compensation $ $ $

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2016
Employee Benefits
Employee Benefits	15. Employee Benefits 401(k) Plan The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Employer contributions vest over four years. Total employer contributions for the years ended December 31, 2016, 2015, and 2014 were approximately $1.0 million, $0.7 million, and $0.7 million, respectively. Defined Benefit Pension Plan In connection with the Merck API Transaction, the Company assumed an obligation associated with a defined-benefit plan for eligible employees of AFP. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFPs turnover rate. The liability under the plan is based on a discount rate of 1.75% as of December 31, 2016 and 2015, respectively. The liability is included in accrued liabilities in the accompanying consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $1.7 million and $1.6 million at December 31, 2016 and 2015, respectively. Expense under the plan was $0.2 million, $0.1 million, and $0.2 million for the years ended December 31, 2016, 2015, and 2014, respectively. For the year ended December 31, 2016, the Company recorded an unrecognized gain of $0.4 million in its accumulated other comprehensive income related to the change in actuarial valuation of the Company’s defined benefit pension plan. For the year ended December 31, 2015, the Company recorded an immaterial amount of unrecognized loss in its accumulated other comprehensive loss related to the change in actuarial valuation of the Company’s defined benefit pension plan. The Company recorded an unrecognized gain of $0.2 million in its accumulated other comprehensive loss during the year ended December 31, 2014, related to the change in actuarial valuation of the Company’s defined benefit pension plan.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies
Commitments and Contingencies	16. Commitments and Contingencies Distribution Agreement with Actavis Inc. In May 2005, the Company entered into an agreement to grant certain exclusive marketing rights for its enoxaparin product to Andrx Pharmaceuticals, Inc., or Andrx, which generally extends to the U.S. retail pharmacy market. To obtain such rights, Andrx made a non-refundable, upfront payment of $4.5 million to the Company upon execution of the agreement which was classified as deferred revenues. Under the agreement, the Company is paid a fixed cost per unit sold to Andrx and also shares in the gross profits (as defined) from Andrx’s sales of the product in the U.S. retail pharmacy market. In November 2006, Watson Pharmaceuticals, Inc., or Watson, acquired Andrx and all of the rights and obligations associated with the agreement. In January 2013, Watson adopted Actavis, Inc. as its new global name. In March 2015, Actavis acquired Allergan plc and adopted Allergan plc as its new global name in June 2015. In January 2012, the Company launched enoxaparin, beginning the seven-year period in which Actavis has the exclusive marketing rights for the Company’s enoxaparin product in the U.S. retail pharmacy market and the start of the Company’s recognition of the $4.5 million deferred revenue over this period on a straight-line basis. On June 30, 2016, the Company and Actavis amended the distribution agreement, which terminated the agreement in December 2016. The Company recognized the remaining balance of the deferred revenue over the period from July 1, 2016 through December 31, 2016, on a straight-line basis as a result of the revised estimate of the contractual period. As of December 31, 2016, the balance of the deferred revenue has been fully recognized. The Company manufactured its enoxaparin product for the retail market according to demand specifications of Actavis. Upon shipment of enoxaparin to Actavis, the Company recognized product sales at an agreed transfer price and records the related cost of products sold. Based on the terms of the Company’s distribution agreement with Actavis, the Company was entitled to a share of the ultimate profits based on the eventual net revenue from enoxaparin sales by Actavis to the end user less the agreed transfer price originally paid by Actavis to the Company. Actavis provided the Company with a quarterly sales report that calculated the Company’s share of Actavis enoxaparin gross profit. The Company recorded its share of Actavis gross profit as a component of net revenue. Supply Agreement with MannKind Corporation On July 31, 2014, the Company entered in a supply agreement with MannKind Corporation, or MannKind, or the Supply Agreement, pursuant to which the Company agreed to manufacture for and supply to MannKind certain quantities of RHI API for use in MannKind’s product Afrezza ® . Under the Supply Agreement, MannKind agreed to purchase annual minimum quantities of RHI API in an aggregate amount of approximately €120.1 million, or approximately $146.0 million, over five years from calendar years 2015 through 2019. Specifically, the minimum annual purchase commitment was approximately €27.1 million in 2015, and approximately €23.3 million each year from 2016 through 2019. On July 31, 2014, upon entering into the Supply Agreement, MannKind paid a non-refundable prepayment to the Company in the amount of €11.0 million, or approximately $14.0 million. Under the Supply Agreement, the non-refundable prepayment was applied towards the 2015 annual commitment. The Company recorded the amount as deferred revenue in 2014, and it was recognized as net revenue in 2015 at the time the product was shipped. In January 2015, the Company entered into a supply option agreement with MannKind, or the Option Agreement, pursuant to which MannKind will have the option to purchase RHI API in excess of the minimum amounts specified in the Supply Agreement in calendar years 2016 through 2019. In the event MannKind elects not to exercise its minimum annual purchase option for any year under the Option Agreement, MannKind is obligated to pay the Company a specified capacity cancellation fee. In October 2015, MannKind informed the Company that it was not exercising the option to purchase additional quantities of RHI API for 2016 under the Option Agreement and paid the Company the specified capacity cancellation fee of $0.8 million. Such capacity cancellation fee was recorded as net revenue in the Company’s consolidated statement of operations for the year ended December 31, 2015. For the year ended December 31, 2016, sales of RHI API to MannKind totaled $6.8 million, which fulfilled the remaining unfulfilled 2015 commitment of RHI under the Supply Agreement. In November 2016, the Company amended the Supply Agreement with MannKind, whereby MannKind’s aggregate total commitment of RHI API under the Supply Agreement has not been reduced; however, the annual minimum purchase commitments of RHI API under the Supply Agreement have been modified and extended through 2023, which timeframe had previously lapsed after calendar year 2019. Specifically, the minimum annual purchase commitment in calendar year 2016 has been cancelled, and the minimum annual purchase commitments in calendar years 2017 through 2023 have been modified to be €2.7 million of insulin in the fourth quarter of 2017, €8.9 million in 2018, €11.6 million in 2019, €15.5 million in 2020 and in 2021, and €19.4 million in 2022 and in 2023. MannKind may request to purchase additional quantities of RHI API in excess of its annual minimum purchase commitments. The Supply Agreement Amendment also (i) shortened the required expiry dates for RHI API delivered to MannKind pursuant to the Supply Agreement, (ii) modified the timing of MannKind’s payment for the minimum annual purchase commitment in calendar year 2017, and (iii) added a pre-payment requirement for purchases of RHI API by MannKind in calendar years 2017 and 2018. The amendment can be renewed for additional, successive two-year terms upon 12 months’ written notice, given prior to the end of the initial term or any additional two-year term. Concurrently with the amendment of the Supply Agreement, the Company amended the Option Agreement with MannKind, whereby the amendment to the Option Agreement extends the timing for payment of the capacity cancellation fee for 2017 and decreases the amounts payable as capacity cancellation fees for 2018 and 2019 in the event MannKind fails to exercise its minimum annual purchase option for any given year. The Company recognized the cancellation fee for 2017 of $1.5 million in net revenues in its consolidated statement of operations for the year ended December 31, 2016, and subsequently collected on this receivable. In addition to, and in consideration of the amended timeframe and other amendments contained in the amendment to the Supply Agreement in the amendment to the Option Agreement, the Supply Agreement Amendment provided the Company right of first refusal to participate in the development and commercialization of Afrezza ® in China through a collaborative arrangement. Collaboration Agreement with a Medical Device Manufacturer The Company has entered into a collaboration agreement with a medical device manufacturer to develop a drug delivery system to be used by the Company for one of its pipeline products. As of December 31, 2016, the Company has paid an upfront payment of $0.5 million and $1.2 million in milestone payments under this agreement, which were classified as research and development expense. The Company is obligated to pay up to an additional $0.8 million if certain milestones are met. As of December 31, 2016, no such obligation existed. Pursuant to the collaboration agreement, if the medical device manufacturer is successful in the development of this drug delivery system and the Company’s pipeline products receive appropriate regulatory approval, the Company is obligated to enter into a commercial supply agreement with such medical device manufacturer for a minimum purchase of 1.0 million units during the first 12 months. Operating Lease Agreements The Company leases real and personal property, in the normal course of business, under various non-cancelable operating leases. The Company, at its option, can renew a substantial portion of its leases, at the market rate, for various renewal periods ranging from one to six years. Rental expense under these leases for the years ended December 31, 2016, 2015, and 2014, was approximately $3.4 million, $3.3 million, and $3.1 million, respectively. Future minimum rental payments under operating leases that have initial or remaining non-cancelable lease terms in excess of 12 months for fiscal years ending December 31 are as follows: Operating Leases (in thousands) 2017 $ 2018 2019 2020 2021 $ Purchase Commitments As of December 31, 2016, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $41.9 million. The Company anticipates that most of these commitments with remaining term in excess of one year will be fulfilled by 2018. The Company entered into agreements with a Chinese governmental entity to acquire land-use rights to real property in Nanjing, China. Under the terms of these agreements, the Company committed to invest capital in its wholly-owned subsidiary, ANP, and to develop these properties as an API manufacturing facility for the Company’s pipeline products. In conjunction with these agreements, ANP modified its business license on July 3, 2012, to increase its authorized capital. As of December 31, 2016, the Company had invested its total registered capital commitment of $61.0 million to ANP. This investment in ANP resulted in cash being transferred from the U.S. parent company to ANP. Per these agreements, in January 2010, the Company acquired certain land-use rights with a carrying value of $1.2 million. In addition, the Company purchased additional land-use rights in November 2012 for $1.3 million. The Company committed to spend approximately $15.0 million in land development. The agreements require the construction of fixed assets on the property and specified a timetable for the construction of these fixed assets. The current pace of development of the property is behind the schedules described in the purchase agreements and, per the purchase agreement, potential monetary penalties could result if the development is delayed or not completed in accordance with the guidelines stated in the purchase agreements. The Company is in discussions with the Chinese government regarding the development and believes that the likelihood of incurring any penalty is remote.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2016
Litigation
Litigation	17. Litigation Enoxaparin Patent Litigation In September 2011, Momenta Pharmaceuticals, Inc., or Momenta, a Boston‑based pharmaceutical company, and Sandoz Inc., or Sandoz, the generic division of Novartis, initiated litigation against the Company for alleged patent infringement of two patents related to testing methods for batch release of enoxaparin, which the Company refers to as the “‘886 patent” and the “‘466 patent.” The lawsuit was filed in the United States District Court for the District of Massachusetts, or the Massachusetts District Court. In October 2011, the Massachusetts District Court issued a preliminary injunction barring the Company from selling its generic enoxaparin product and also requiring Momenta and Sandoz to post a $100.1 million bond. The preliminary injunction was stayed by the United States Court of Appeals for the Federal Circuit, or the Federal Circuit, in January 2012, and reversed by the Federal Circuit in August 2012. In January 2013, the Company moved for summary judgment of non‑infringement of both patents. Momenta and Sandoz withdrew their allegations as to the ‘466 patent, and in July 2013, the Massachusetts District Court granted the Company’s motion for summary judgment of non‑infringement of the ‘886 patent and denied Momenta and Sandoz’s motion for leave to amend their infringement contentions. On January 24, 2014, the Massachusetts District Court judge entered final judgment in the Company’s favor on both patents. Momenta and Sandoz also filed a motion to collect attorneys’ fees and costs relating to a discovery motion which the Massachusetts District Court granted. On May 9, 2016, the Massachusetts District Court issued an order imposing fees and costs of approximately $0.4 million in relation to this discovery motion. This amount has been accrued in the general and administrative expense for the quarter ended March 31, 2016 . On January 30, 2014, Momenta and Sandoz filed a notice of appeal to the Federal Circuit appealing the court’s final judgment including summary judgment denying Momenta and Sandoz’s motion for leave to amend their infringement contentions. Following appeal briefing filed by the parties, t he Federal Circuit held oral argument on May 4, 2015. On November 10, 2015, the Federal Circuit panel affirmed-in-part and vacated-in-part the decision of the Massachusetts District Court granting summary judgment of non-infringement as to the Company, and it remanded the case to the Massachusetts District Court for further proceedings consistent with its opinion. The Federal Circuit panel affirmed the Massachusetts District Court’s holding in the Company’s favor that the Company does not infringe under 35 U.S.C. 271(g), and the panel vacated the grant of summary judgment to the extent it was based on the determination that the Company’s activities fall within the 35 U.S.C. 271(e)(1) safe harbor. The Federal Circuit panel also left to the Massachusetts District Court’s discretion whether to reconsider on remand its denial of leave for Momenta and Sandoz to amend their infringement contentions. On January 11, 2016, the Company filed a Petition for Rehearing En Banc with the Federal Circuit. On February 17, 2016, the Federal Circuit denied the Company’s Petition, and the Federal Circuit issued its mandate on February 24, 2016, whereby the case returned to the Massachusetts District Court for further proceedings. On March 18, 2016, the parties filed a joint status report with the Massachusetts District Court. On June 21, 2016, the Massachusetts District Court granted Momenta and Sandoz’s Motion for Leave to Amend its Infringement Contentions. In light of Momenta and Sandoz’s Amended Infringement Contentions and recent changes in Supreme Court precedent since the case was stayed in 2012, the Company sought to amend its Non-Infringement and Invalidity Contentions. The Massachusetts District Court then held a status conference on July 6, 2016 and referred the issue of the Company’s amended contentions to the Magistrate Judge for briefing and further informed the parties that replies to any Summary Judgment motion are due in May 2017 and that trial is set to begin on July 10, 2017. On July 15, 2016, the Massachusetts District Court entered the Amended Scheduling Order setting the end of any remaining fact discovery for November 22, 2016 and the end of expert discovery for March 24, 2017. Fact discovery closed on November 22, 2016. The parties have exchanged opening and rebuttal expert reports. On July 18, 2016, the Company submitted its Motion for Leave to Amend Its Non-Infringement and Invalidity Contentions and Momenta and Sandoz responded on July 25, 2016. In light of the new arguments made in their response, the Company further filed a Motion For Leave to Reply in Further Support of Defendants’ Motion for Leave to Amend Non-Infringement and Invalidity Contentions, which was granted. A hearing was held on August 23, 2016, where the Magistrate Judge ordered the Company to file its proposed amended contentions, which it filed on August 31, 2016. On February 4, 2017, the Magistrate Judge issued an order denying the Company leave to amend its contentions. The Company filed objections to this order with the District Court on February 21, 2017. The Massachusetts District Court has not yet ruled on the Company’s pending motion regarding its amended contentions. In parallel with the Massachusetts District Court proceedings, the Company appealed the Federal Circuit’s decision to vacate the grant of the Company’s summary judgment to the extent it was based on the determination that the Company’s activities are protected under the Safe Harbor. The Company filed a Petition for a Writ of Certiorari with the Supreme Court on May 17, 2016. Momenta and Sandoz initially waived their right to respond to the petition; however, on May 31, 2016, the Supreme Court requested a response from Momenta and Sandoz. The response from Momenta and Sandoz was initially due on June 30, 2016, but they requested an extension. Momenta and Sandoz filed their response on August 1, 2016. On October 3, 2016, the Supreme Court declined the Petition for a Writ of Certiorari. The Company will continue to vigorously defend this case in the Massachusetts District Court. The Company intends to attempt to collect the $100.1 million bond posted by Momenta and Sandoz following a decision on the merits, provided that the Company prevails in Massachusetts District Court. False Claims Act Litigation In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California, or the California District Court, alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox ® product. If the Company is successful in this litigation, it could be entitled to a portion of any damage award that the government ultimately may recover from Aventis. In October 2011, the California District Court unsealed the Company’s complaint. On February 28, 2014, Aventis filed a motion for summary judgment on the issue of the adequacy of the Company’s notice letter to the government, and the California District Court denied Aventis’ motion for summary judgment in a final order it issued on May 12, 2014. On June 9, 2014, at Aventis’ request, the California District Court issued an order certifying for appeal its order denying Aventis’ motion for summary judgment. On June 9, 2014, Aventis filed with the United States Court of Appeals for the Ninth Circuit, or the Ninth Circuit, a petition for permission to appeal the California District Court’s denial of Aventis’ motion for summary judgment, and the Company filed an opposition to Aventis’ petition on June 19, 2014. On August 22, 2014, the Ninth Circuit granted Aventis’ petition. The parties have completed and filed their respective appeal briefs with the Ninth Circuit. On November 10, 2016, the Ninth Circuit heard oral argument on the pending appeal and took the matter under submission. The California District Court set an evidentiary hearing for July 7, 2014 on the “original source” issue, a key element under the False Claims Act. The evidentiary hearing was conducted as scheduled, from July 7, 2014 through July 10, 2014. On July 13, 2015, the California District Court issued a ruling concluding that the Company is not an original source under the False Claims Act and entered final judgment dismissing the case for lack of subject matter jurisdiction. On July 20, 2015, the Company filed with the Ninth Circuit a notice of appeal of the California District Court’s dismissal of the case, and Aventis filed a notice of cross-appeal on August 5, 2015. On November 12, 2015, Aventis filed a pleading asking that the California District Court impose various monetary penalties and fines against the Company, including disgorgement of enoxaparin revenues and attorneys’ fees expended by Aventis in this action, based on Aventis’s allegations that the Company engaged in sanctionable conduct. On November 23, 2015, the California District Court issued an order setting forth a procedure for sanctions proceedings as to the Company as well as its outside counsel. On December 24, 2015, the Company filed a pleading with the California District Court opposing the imposition of sanctions, and on January 20, 2016, Aventis filed a response pleading further pressing for the imposition of sanctions. On May 4, 2016, the California District Court issued three orders requesting that the Company and its outside counsel file a document showing cause as to why sanctions should not be imposed and to set up a conference call with the partiers and the court to discuss whether any discovery and/or a hearing is necessary. On June 13, 2016, the Company and its outside counsel each filed responses to the court’s order to show cause as to why sanctions should not be imposed. On July 21, 2016, Aventis filed a response contending that the court should impose sanctions. On February 10, 2017, the Court held a show cause hearing regarding the potential imposition of sanctions and took the matter under submission. The Company intends to continue to vigorously defend against any such imposition of sanctions. On March 28, 2016, the Company filed its opening brief with the Ninth Circuit Court of Appeals setting forth detailed arguments as to why the False Claims Act litigation should not have been dismissed by the California District Court. On June 20, 2016, Aventis filed its principal brief in the appeal, responding to the Company’s arguments regarding dismissal of the False Claims Act litigation, and setting forth Aventis’s argument that it should be awarded attorneys’ fees and expenses. On September 19, 2016, the Company filed its reply brief to Aventis’s principal brief. On October 3, 2016, Aventis filed its reply brief in support of its cross-appeal of the District Court’s denial of attorneys’ fees. The Ninth Circuit has scheduled oral arguments to be heard on November 10, 2016. On November 10, 2016, the Ninth Circuit heard oral argument on the pending appeals and took them under submission. California Employment Litigation On January 6, 2015, the Company received a formal demand from Plaintiff’s counsel in an employment related lawsuit captioned Eva Hernandez v. International Medication Systems Limited, in connection with a complaint originally filed on February 4, 2013, in the Superior Court of California County of Los Angeles, or the Court, by plaintiff Eva Hernandez on behalf of herself and others similarly situated. Plaintiff’s complaint included alleged violations of the California Labor Code stemming from the Company’s alleged timekeeping practices, as well as other similar and related claims brought under California law. In the complaint, Plaintiff sought damages and related remedies under California law, as well as various penalty payments under the California Labor Code, on behalf of herself and others similarly situated. On April 7, 2015, solely to resolve the dispute, minimize disruption to the Company due to ongoing litigation, and other similar and related factors (but unrelated to the alleged merits of Plaintiff’s claims), the Company reached an agreement in principle to settle this matter on a class-wide basis for a total amount of $3.2 million, plus applicable payroll taxes. The Joint Stipulation of Settlement as executed by the parties was filed with the Court on June 2, 2015. On July 1, 2015, the Court preliminarily approved the settlement, and on November 5, 2015, the Court entered an order granting final approval of the settlement. On May 13, 2016, the court reviewed and approved the final distribution report. The case was removed from the Court’s Civil Active Case List. Momenta/Sandoz Antitrust Litigation On September 17, 2015, the Company initiated a lawsuit by filing a complaint in the California District Court against Momenta and Sandoz, or Defendants. The Company’s complaint generally asserts that Defendants have engaged in certain types of illegal, monopolistic, and anticompetitive conduct giving rise to various causes of action against them. On December 9, 2015, Defendants filed a motion to dismiss and a motion to transfer the case to the District of Massachusetts. On January 4, 2016, the Company filed oppositions to both motions. On January 26, 2016, the California District Court granted Defendants’ motion to transfer and did not rule on Defendants’ motion to dismiss. Accordingly, the case was transferred to the District of Massachusetts. On February 9, 2016, the Company filed a writ of mandamus with the Ninth Circuit to attempt to appeal the California District Court’s granting of Defendants’ motion to transfer to the District of Massachusetts. The Ninth Circuit denied this petition on May 20, 2016, and as such the case will remain before the District of Massachusetts. On July 27, 2016, the Massachusetts District Court granted Defendants’ motion to dismiss based upon an antitrust immunity doctrine, without addressing the substantive merits of the claims. On August 25, 2016, the Company filed with the First Circuit Court of Appeals a notice of appeal of the Massachusetts District Court’s dismissal of the antitrust case. Other Litigation The Company is also subject to various other claims and lawsuits from time-to-time arising in the ordinary course of business. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events
Subsequent Events	18. Subsequent Events Sale of Fourteen Injectable ANDAs In February 2017, the Company sold the 14 ANDAs it acquired in March 2016 from Hikma to an unrelated party. The consideration included a purchase price of $6.4 million of which (i) the amount of $1.0 million was received upon closing, and the remaining $5.4 million will be paid upon certain milestones. If the purchaser is not able to achieve these milestones by December 31, 2017, the purchaser will pay the remaining payments within 30 days of December 31, 2017. In addition to the purchase price, the purchaser agrees to pay the Company a royalty fee equal to 2% of net sales, which are derived from purchaser’s sales of the products for a period from February 2017 through February 2027. The Company is also subject to certain indemnification liability payable to the purchaser, which is limited up to $0.6 million. As of December 31, 2016, the 14 ANDAs had a carrying amount of $3.8 million. Discontinuation of epinephrine injection, USP vial product In March 2017, the FDA has requested the Company to discontinue the manufacturing and distribution of its epinephrine injection, USP vial product, which has been marketed under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. The Company is currently in discussions with the FDA regarding the timing of the discontinuation of this product. For the year ended December 31, 2016, the Company recognized $18.6 million in net revenues for the sale of this product. The charge of $3.3 million was included in the cost of revenues in its consolidated statements of operations for the year ended December 31, 2016 to adjust the related inventory items and firm purchase commitment to their net realizable value due to the anticipated discontinuation of the product.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Data
Quarterly Financial Data	19. Quarterly Financial Data (Unaudited) 2016 Quarters First Second Third Fourth (in thousands, except per share data) Net revenues Finished pharmaceutical products $ $ $ $ API Total net revenues $ $ $ $ Gross profit Finished pharmaceutical products $ $ $ $ API Total gross profit $ $ $ $ Net income (loss) $ $ $ $ Weighted-average shares used to compute net income (loss) per share Basic Diluted Net income (loss) per share Basic $ $ $ $ Diluted $ $ $ $ 2015 Quarters First Second Third Fourth (in thousands, except per share data) Net revenue Finished pharmaceutical products $ $ $ $ API Total net revenues $ $ $ $ Gross profit Finished pharmaceutical products $ $ $ $ API Total gross profit $ $ $ $ Net income (loss) $ $ $ $ Weighted-average shares used to compute net income (loss) per share Basic Diluted Net income (loss) per share Basic $ $ $ $ Diluted $ $ $ $ Net income (loss) per share amounts for the fiscal quarters have been calculated independently and may not in the aggregate equal the amount for the full year. During the fourth quarter of 2015, the Company identified an immaterial error in each of its previously reported quarters of 2015, primarily pertaining to the result of not recognizing non-operating expense for certain foreign currency transactions. The Company corrected the immaterial error in the fourth quarter of 2015, resulting in a decrease to net income of $1.1 million. Based on management's evaluation of the materiality of the error from a qualitative and quantitative perspective as required by authoritative guidance, the Company concluded that correcting the error had no material impact on any of the Company's previously issued interim financial statements and had no effect on the trend of financial results.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain amounts in the prior years’ consolidated statements of operations have been reclassified to conform to the current year presentation. This reclassification has no impact on net income or cash flows. All significant intercompany activity has been eliminated in the preparation of the consolidated financial statements. The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS; (2) Armstrong Pharmaceuticals, Inc., or Armstrong; (3) Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; (4) Nanjing Letop Fine Chemistry Co., Ltd., or Letop, (5) Amphastar France Pharmaceuticals, S.A.S., or AFP, (6) Amphastar UK Ltd., or AUK, and (7) International Medication Systems (UK) Limited, or IMS UK.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, provision for chargebacks, liabilities for product returns, adjustment to cost for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
Foreign Currency	Foreign Currency The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary, ANP, and its U.K. subsidiary, AUK, is the U.S. dollar, or USD. ANP maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s statements of operations. The Company’s French subsidiary, AFP, Chinese subsidiary, Letop, and U.K. subsidiary, IMS UK, maintain their books of record in Euros, Chinese Yuan, and Great Britain Pounds, respectively, which are the local currencies and have been determined to be their respective functional currencies. These books are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the years ended December 31, 2016, 2015, and 2014 were a $1.5 million loss, $2.0 million loss, and a $2.7 million loss, respectively. Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
Comprehensive Income (Loss)	Comprehensive Income (Loss) For the years ended December 31, 2016, 2015 and 2014, the Company included its foreign currency translation gain or loss and change in pension obligation of its defined benefit pension plan as part of its comprehensive income (loss).
Shipping and Handling Costs	Shipping and Handling Costs For the years ended December 31, 2016, 2015, and 2014, the Company included shipping and handling costs of approximately $2.4 million, $2.6 million, and $2.5 million, respectively, in selling, distribution and marketing expenses in the accompanying consolidated statements of operations.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company’s research and development activities including salaries and related employee benefits, costs associated with clinical trials, nonclinical research and development activities, regulatory activities, research‑related overhead expenses and fees paid to external service providers. The Company may produce inventories prior to or with the expectation of receiving marketing authorization in the near term, based on operational decisions about the most effective use of existing resources. This inventory is referred to as pre‑launch inventory. It is the Company’s accounting policy that the pre-launch inventory is capitalized if it has a probable future economic benefit. If marketing authorization is received and previously expensed pre‑launch inventory is sold, such sales may contribute up to a 100% margin to the Company’s operating results. Pre‑launch inventory costs include cost of work in process, materials, and finished drug products. As of December 31, 2016, 2015, and 2014, the Company did not have any capitalized pre-launch inventory.
Financial Instruments	Financial Instruments The carrying amounts of cash and cash equivalents, short-term investments, restricted short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 12). The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash, money market accounts, money market funds, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.
Restricted Short Term Investments and Short-Term Investments	Restricted Short‑Term Investments and Short-Term Investments Restricted short‑term investments as of December 31, 2016 and 2015 included $1.4 million and $1.3 million, respectively, in certificates of deposit, which are the collateral required for the Company to qualify for workers’ compensation self‑insurance and are available to meet the Company’s workers’ compensation obligations on a current basis, as needed. These funds are classified as current assets. The Company’s short‑term investments include municipal bonds with original maturities greater than three months and are classified as held-to-maturity. The municipal bonds are carried at amortized cost in the Company’s consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The Company does not intend to and will not be required to sell the investments before recovery of their amortized cost basis.
Allowance for Doubtful Accounts Receivable	Allowance for Doubtful Accounts Receivable The Company evaluates the collectability of accounts receivable based on a combination of factors. When the Company is aware of circumstances that may impair a customer’s ability to pay subsequent to the original sale, the Company records a specific allowance to reduce the amounts receivable to the amount that the Company reasonably believes to be collectable. For all other customers, the Company recognizes an allowance for doubtful accounts based on factors that include the length of time the receivables are past due, industry and geographic concentrations, the current business environment and historical collection experience. As of December 31, 2016 and 2015, the Company's allowance for doubtful accounts was $0.3 million and $0.7 million, respectively.
Inventories	Inventories Inventories consist of currently marketed products and products manufactured under contract. Inventories are stated at the lower of cost or net realizable value, using the first‑in, first‑out method. Provisions are made for slow‑moving, unsellable, or obsolete items. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. The charge of $7.3 million was included in the cost of revenues in the Company’s consolidated statements of operations for the year ended December 31, 2016 to adjust the Company’s inventory items to their net realizable value, including $3.1 million related to enoxaparin inventory items due to a decrease in the forecasted average selling price and $3.3 million related to Epinephrine Injection, USP vial inventory items and firm purchase commitments due to the anticipated discontinuation of the product.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost or, in the case of assets acquired in a business combination, at fair value on the purchase date. Depreciation and amortization expense is computed using the straight‑line method over the estimated useful lives of the related assets as follows: Buildings 20 - 31 years Machinery and equipment 2 - 12 years Furniture and fixtures 3 - 7 years Automobiles 4 - 5 years Leasehold improvements Lesser of remaining lease term or useful life
Intangible Assets	Intangible Assets Intangible assets with finite lives are amortized using the straight-line method over the period the asset is expected to contribute directly or indirectly to the future cash flows of the Company as follows: Product rights 5 - 15 years Patents 10 - 20 years Land-use rights 37 - 50 years
Impairment of Long Lived Assets, including Identifiable Definite-Lived Intangible Assets	Impairment of Long‑Lived Assets, including Identifiable Definite-Lived Intangible Assets The Company reviews long-term assets and identifiable definite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets (assets to be held and used) or fair value less cost to sell (assets to be disposed of). The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.
Deferred Income Taxes	Deferred Income Taxes The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share‑based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share‑based awards.
Impairment of Indefinite-Lived Intangible Asset and Goodwill	Impairment of Indefinite-Lived Intangible Asset and Goodwill The Company reviews indefinite‑lived intangible asset and goodwill for impairment in the fourth quarter of each year or more frequently if indicators of impairment are present. When the Company chooses to perform a qualitative assessment, it evaluates economic, industry and company-specific factors as an initial step. If the Company determines it is more likely than not that the indefinite-lived intangible asset is impaired or the fair value of a reporting unit is less than its carrying amount, further quantitative impairment process is then performed; otherwise, no further testing is required. An impairment loss is recorded if the asset’s fair value is less than its carrying value. The Company also periodically reviews the indefinite-lived intangible asset to determine if events and circumstances continue to support an indefinite useful life. If the life is no longer indefinite, the asset is tested for impairment. The carrying value, after recognition of any impairment loss, is amortized over its remaining useful life.
Self-Insured Claims	Self-Insured Claims The Company is primarily self-insured, up to certain limits, for workers’ compensation claims. The Company has purchased stop-loss insurance, which will reimburse the Company for individual claims in excess of $350,000 annually or aggregate claims exceeding $1.9 million annually. Operations are charged with the cost of claims reported and an estimate of claims incurred but not reported. A liability for unpaid claims and the associated claim expenses, including incurred but not reported losses, is actuarially determined and reflected in accrued liabilities in the accompanying consolidated balance sheets. Total expense under the program was approximately $1.6 million, $1.2 million, and $1.0 million, for the years ended December 31, 2016, 2015 and 2014, respectively. The self-insured claims liability was $3.5 million and $2.7 million at December 31, 2016 and 2015, respectively. The determination of such claims and expenses and the appropriateness of the related liability is reviewed periodically and updated, as necessary. Changes in estimates are recorded in the period identified.
Business Combinations	Business Combinations If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the asset acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to effect a business combination are expensed in the periods in which the costs are incurred. When the operations of the acquired businesses were not material to the Company’s consolidated financial statements, no pro forma presentation is disclosed.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required regarding customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). Based on the related accounting standards update issued in August 2015, this guidance will be effective for the Company in 2018, including interim periods within the year. While the Company is still in the process of evaluating the effect of adoption on its consolidated financial statements and is currently assessing its contracts with customers and sale of nonfinancial assets. The Company anticipates it will expand its consolidated financial statement disclosures in order to comply with the new guidance. The Company expects to select the modified retrospective transition method upon the adoption. In addition, in February 2017, the FASB issued an accounting standards update to clarify the scope of the model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets and to add guidance for partial sales of nonfinancial assets. This guidance is to be applied using a full retrospective method or a modified retrospective method as outlined in the guidance and is effective at the same time as discussed above. The Company is currently evaluating the provisions of this guidance and assessing its potential impact on the Company’s financial statements and disclosures. In July 2015, the FASB issued an accounting standards update which requires entities to measure most inventories at the lower of cost or net realizable value, or NRV, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is measured at the lower of cost or net realizable value, which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company has elected to adopt the guidance early and apply the guidance prospectively in its interim quarter beginning October 1, 2016. The adoption of this accounting guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. In November 2015, the FASB issued an accounting standards update to the balance sheet classification of deferred taxes. Under existing standards, deferred taxes for each tax-paying jurisdiction are presented as a net current asset or liability and net long-term asset or liability. To simplify presentation, the new guidance will require that all deferred tax assets and liabilities, along with related valuation allowances, be classified as long-term on the balance sheet. As a result, each tax-paying jurisdiction will now only have one net long-term deferred tax asset or liability. The new guidance does not change the existing requirement that prohibits offsetting deferred tax liabilities from one jurisdiction against deferred tax assets of another jurisdiction. The guidance is effective for annual periods beginning after December 15, 2016, and interim reporting periods therein. Early adoption is permitted. The new guidance may be applied prospectively or retrospectively. The Company has elected to adopt the guidance early and apply the guidance prospectively. Therefore, prior periods were not retrospectively adjusted. The reclassification of the Company’s deferred tax assets and liabilities does not have any impact on the Company’s net income or cash flow; thus, the adoption of the guidance does not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued an accounting standards update that is aimed at making leasing activities more transparent and comparable, and which requires substantially all leases to be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements for the reporting periods in which the guidance is adopted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In March 2016, the FASB issued an accounting standards update that is aimed at improving the employee share-based payment accounting. The standard update simplifies the accounting for employee share-based payments and involves several aspects of the accounting for share-based transactions, including the potential timing of expenses, the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The guidance is effective for annual periods during the year ended December 15, 2017, and interim reporting periods therein. Early adoption is permitted. The adoption of the guidance is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. In June 2016, the FASB issued an accounting standards update that is aimed at providing financial statement users with more useful information about the expected credit losses on financial instruments and other commitments to extend credit. The standard update changes the impairment model for financial assets measured at amortized cost, requiring presentation at the net amount expected to be collected. The measurement of expected credit losses requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Available-for-sale debt securities with unrealized losses will be recorded through an allowance for credit losses. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted for annual periods after 2019. The Company will be required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In August 2016, the FASB issued an accounting standards update that is aimed at addressing certain issues regarding classifications of certain cash receipt and cash payment on the statement of cash flows where diversity in practice was identified. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted. The Company will be required to apply the guidance retrospectively in the first interim and annual periods in which the guidance is adopted. The Company does not believe that the adoption of this accounting guidance will have a material impact on the Company’s consolidated financial statements and related disclosures. In October 2016, the FASB issued an accounting standards update that requires an entity to recognize the income tax consequences of intra-entity transfer of an asset other than inventory when the transfer occurs. The guidance is effective for the Company's interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted as of the beginning of an annual reporting period for which financial statements, interim or annual, have not been issued. The amendments will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In November 2016, the FASB issued an accounting standards update that will require entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, the Company will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The guidance is effective for the Company's interim and annual reporting periods during the year ending December 31, 2018. Early adoption is permitted, including adoption in an interim period. The amendments will be applied using a retrospective transition method to each period presented. The Company will be required to apply the guidance retrospectively when adopted. The Company does not believe that the adoption of this accounting guidance will have a material impact on its consolidated financial statements and related disclosures. In January 2017, the FASB issued an accounting standards update that provides guidance to assist entities with evaluating when a set of transferred assets and activities is a business. Under the updated guidance, a set is not a business if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar assets. If the threshold is not met, the update requires that, to be a business, the set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. The definition of outputs was also aligned with ASC 606 by focusing on revenue-generating activities. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2018, and prospectively applicable to any transactions occurring within the period of adoption. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued an accounting standards update that eliminates the requirement to calculate the implied fair value of goodwill. An entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. The guidance is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2020, and applied on a prospective basis. Early adoption is permitted for interim and annual goodwill impairment testing dates after January 1, 2017. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements and related disclosures

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies
Schedule of estimated useful life of property, plant and equipment	Buildings 20 - 31 years Machinery and equipment 2 - 12 years Furniture and fixtures 3 - 7 years Automobiles 4 - 5 years Leasehold improvements Lesser of remaining lease term or useful life
Schedule of estimated useful life of intangible assets	Product rights 5 - 15 years Patents 10 - 20 years Land-use rights 37 - 50 years

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Business Acquisition
Schedule of payments for business acquisition	U.S. Euros Dollars (in thousands) At Closing, April 2014 € $ December 2014 December 2015 December 2016 December 2017 € $
Schedule of estimated fair values of the assets acquired and liabilities assumed	Fair Value U.S. Euros Dollars (in thousands) Inventory € $ Real property Machinery and equipment Intangibles Goodwill Total assets acquired € $ Accrued liabilities € $ Deferred tax liabilities Total liabilities assumed Total fair value of consideration transferred € $
Schedule of pro forma information related to the acquisition	Year Ended December 31, 2014 2013 (in thousands, except per share data) Net revenues $ $ Net loss Diluted net loss per share $ $

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2016
Revenue Recognition
Schedule of chargeback provision analysis	Year Ended December 31, 2016 2015 (in thousands) Beginning balance $ $ Provision related to sales made in the current period Credits issued to third parties Ending balance $ $
Schedule of product return liability analysis	Year Ended December 31, 2016 2015 (in thousands) Beginning balance $ $ Provision for product returns Credits issued to third parties Ending balance $ $

Income (Loss) per Share (Tables

Income (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Income (Loss) per Share
Schedule of basic and diluted net income (loss) per share calculation	Year Ended December 31, 2016 2015 2014 (in thousands, except per share data) Basic and dilutive numerator: Net income (loss) $ $ $ Denominator: Weighted-average shares outstanding — basic Net effect of dilutive securities: Incremental shares from equity awards — — Weighted-average shares outstanding — diluted Net income (loss) per share — basic $ $ $ Net income (loss) per share — diluted $ $ $

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting
Schedule of financial information by reporting segment	Year Ended December 31, 2016 2015 2014 (in thousands) Net revenues: Finished pharmaceutical products $ $ $ API Total net revenues Gross profit: Finished pharmaceutical products API Total gross profit Operating expenses Income (loss) from operations Non-operating expenses Income (loss) before income taxes $ $ $
Schedule of net revenues in the finished pharmaceutical products segment	Year Ended December 31, 2016 2015 2014 (in thousands) Finished pharmaceutical products net revenues: Enoxaparin $ $ $ Naloxone Lidocaine Phytonadione Epinephrine Other finished pharmaceutical products Total finished pharmaceutical products net revenues $ $ $
Schedule of net revenues and long-lived assets by geographic region	Net Revenue Long-Lived Assets Year Ended December 31, December 31, 2016 2015 2014 2016 2015 (in thousands) United States $ $ $ $ $ China — — — France United Kingdom — — — — Total $ $ $ $ $

Customer and Supplier Concent33

Customer and Supplier Concentration (Tables)	12 Months Ended
	Dec. 31, 2016
Customer and Supplier Concentration
Schedule of accounts receivable and net revenues by major customer	% of Total Accounts % of Net Receivable Revenue December 31, December 31, Year Ended December 31, 2016 2015 2016 2015 2014 Actavis (1) % % % % % AmerisourceBergen % % % % % Cardinal Health % % % % % MannKind Corporation % % % % % McKesson % % % % %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Measurements
Schedule of financial assets and liabilities measured on a recurring basis	Quoted Prices in Active Markets Significant Other Significant Other for Identical Observable Unobservable Assets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2016 $ $ $ — $ — Cash equivalents $ $ $ — $ — Restricted short-term investments — — Fair value measurement as of December 31, 2015 $ $ $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets
Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class	Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Cortrosyn ® product rights 12 $ $ $ IMS (UK) international product rights (1) 10 Acquired ANDAs (2) 15 Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill - Finished pharmaceutical products * — Subtotal * — As of December 31, 2016 * $ $ $ Weighted-Average Accumulated Life (Years) Original Cost Amortization Net Book Value (in thousands) Definite-lived intangible assets Cortrosyn ® product rights 12 $ $ $ Patents 10 Land-use rights 39 Other intangible assets 1 Subtotal 12 Indefinite-lived intangible assets Trademark * — Goodwill - Finished pharmaceutical products * — Subtotal * — As of December 31, 2015 * $ $ $ * Intangible assets with indefinite lives have an indeterminable average life. (1) In August 2016, the Company acquired International Medication Systems (UK) Limited from UCB PHARMA GmbH for $7.7 million. The fair value of the marketing authorization was $9.2 million as of the acquisition date (see Note 3). (2) In March 2016, the Company acquired 14 ANDAs representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million (see Note 3). In February 2017, the Company sold the 14 ANDAs to an unrelated party purchaser for $6.4 million (see note 18).
Schedule of changes in carrying amounts of goodwill	December 31, 2016 2015 (in thousands) Beginning balance $ $ Goodwill related to acquisition of business — Currency translation and other adjustments Ending balance $ $
Schedule of finite-lived intangible assets, future amortization expense	(in thousands) 2017 $ 2018 2019 2020 2021 Thereafter Total amortizable intangible assets Indefinite-lived intangibles Total intangibles (net of accumulated amortization) $

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventories
Schedule of inventories	December 31, 2016 2015 (in thousands) Raw materials and supplies $ $ Work in process Finished goods Total inventories $ $

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant, and Equipment
Schedule of property, plant, and equipment	December 31, 2016 2015 (in thousands) Buildings $ $ Leasehold improvements Land Machinery and equipment Furniture, fixtures, and automobiles Construction in progress Total property, plant, and equipment Less accumulated depreciation Total property, plant, and equipment, net $ $

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt
Schedule of debt	December 31, 2016 2015 (in thousands) Loans with East West Bank Mortgage payable matured January 2016 $ — $ Mortgage payable matured September 2016 — Equipment loan due April 2017 Line of credit facility due September 2017 — — Equipment loan due January 2019 Mortgage payable due February 2021 — Equipment credit line due September 2021 — Mortgage payable due October 2026 — Loans with Cathay Bank Line of credit facility due May 2018 — — Acquisition loan due April 2019 Mortgage payable due April 2021 Loans with Seine-Normandie Water Agency French government loan 1 due March 2018 French government loan 2 due June 2020 French government loan 3 due July 2021 Payment Obligation to Merck Equipment under Capital Leases Total debt and capital leases Less current portion of long-term debt and capital leases Long-term debt and capital leases, net of current portion $ $
Schedule of Maturities of Long-term Debt [Table Text Block]	Capital Debt Leases Total (in thousands) 2017 $ $ 2018 2019 2020 2021 Thereafter — $ $ $

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes
Schedule of income (loss) before income taxes	Year Ended December 31, 2016 2015 2014 (in thousands) Income (loss) before income taxes: United States $ $ $ Foreign Total income (loss) before taxes $ $ $
Summary of provision (benefit) for income taxes	Year Ended December 31, 2016 2015 2014 (in thousands) Current provision (benefit): Federal $ $ $ State Foreign Total current provision Deferred provision (benefit): Federal State Foreign Total deferred benefit Total provision (benefit) for income taxes $ $ $
Schedule of reconciliation of the statutory federal income tax rate	Year Ended December 31, 2016 2015 2014 Statutory federal income tax (benefit) % % % State tax expense, net of federal tax benefit Foreign tax rate differences Foreign valuation allowance — Qualified production activities deduction — — Research and development credits Share-based compensation Other — Effective tax rate (benefit) % % %
Summary of deferred tax assets and liabilities	December 31, 2016 2015 (in thousands) Deferred tax assets: Net operating loss carryforward $ $ State income taxes Inventory capitalization and reserve Deferred revenue — Accrued payroll and benefits Share-based compensation Research and development credits Alternative minimum tax Accrued professional fees Product return allowance Accrued chargebacks Bad debt reserve Intangibles Accrued for workers’ compensation insurance Total deferred tax assets Deferred tax liabilities: Depreciation/amortization Intangibles Federal impact of state deferred taxes Other Total deferred tax liabilities Valuation allowance Net deferred tax assets $ $
Schedule of unrecognized tax benefits	December 31, 2016 2015 2014 (in thousands) Balance at the beginning of the year $ $ $ Additions based on tax positions related to prior years — — Additions based on tax positions related to the current year Deductions based on statute of limitations — — Balance at the end of the year $ $ $

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity
Schedule of key assumptions to determine fair value of options	Year Ended December 31, 2016 2015 2014 Average volatility % % % Risk-free interest rate % % % Weighted-average expected life in years Dividend yield rate — % — % — %
Schedule of the summary of option activity under all plans	Weighted-Average Weighted-Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term (Years) Value (1) (in thousands) Outstanding as of December 31, 2015 $ Options granted Options exercised Options cancelled Options expired Outstanding as of December 31, 2016 $ $ Exercisable as of December 31, 2016 $ $ (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the Company’s common stock for those awards that have an exercise price below the estimated fair value at December 31, 2016.
Schedule of information relating to options grants	Year Ended December 31, 2016 2015 2014 (in thousands, except per share data) Weighted-average grant date fair value $ $ $ Intrinsic value of options exercised Cash received Total fair value of the options vested during the year
Schedule of the summary of nonvested options status	Weighted-Average Grant Date Options Fair Value Nonvested as of December 31, 2015 $ Options granted Options vested Options forfeited Nonvested as of December 31, 2016
Schedule of information relating to RSU grants and deliveries	Total Fair Market Value of RSUs Issued Total RSUs as Issued Compensation (1) (in thousands) RSUs outstanding at December 31, 2015 RSUs granted $ RSUs forfeited Common stock delivered RSUs surrendered for taxes RSUs outstanding at December 31, 2016 (1) The total FMV is derived from the number of RSUs granted times the current stock price on the date of grant.
Schedule of recorded share-based compensation expense under all plans	Year Ended December 31, 2016 2015 2014 (in thousands) Cost of revenues $ $ $ Operating expenses: Selling, distribution, and marketing General and administrative Research and development Total share-based compensation $ $ $

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies
Schedule of future minimum rental payments for operating leases	Operating Leases (in thousands) 2017 $ 2018 2019 2020 2021 $

Quarterly Financial Data (Una42

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Data
Schedule of Quarterly Financial Information	2016 Quarters First Second Third Fourth (in thousands, except per share data) Net revenues Finished pharmaceutical products $ $ $ $ API Total net revenues $ $ $ $ Gross profit Finished pharmaceutical products $ $ $ $ API Total gross profit $ $ $ $ Net income (loss) $ $ $ $ Weighted-average shares used to compute net income (loss) per share Basic Diluted Net income (loss) per share Basic $ $ $ $ Diluted $ $ $ $ 2015 Quarters First Second Third Fourth (in thousands, except per share data) Net revenue Finished pharmaceutical products $ $ $ $ API Total net revenues $ $ $ $ Gross profit Finished pharmaceutical products $ $ $ $ API Total gross profit $ $ $ $ Net income (loss) $ $ $ $ Weighted-average shares used to compute net income (loss) per share Basic Diluted Net income (loss) per share Basic $ $ $ $ Diluted $ $ $ $

Summary of Significant Accoun43

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Gains and losses of intercompany foreign currency transactions	$ (1,500,000)	$ (2,000,000)	$ (2,700,000)
Shipping and handling costs	2,400,000	2,600,000	2,500,000
Allownace for doubtful accounts	300,000	700,000
Inventory adjustment included in cost of revenues	7,300,000
Restricted short-term investments	1,390,000	1,285,000
Amount retained, individual claims	350,000
Amount retained, aggregate claims	1,900,000
Actuarially Determined Self-insurance Expense	1,600,000	1,200,000	$ 1,000,000
Self-insurance Claims Liability	3,500,000	$ 2,700,000
Enoxaparin
Inventory adjustment included in cost of revenues	3,100,000
Epinephrine
Inventory adjustment included in cost of revenues	$ 3,300,000

Summary of Significant Accoun44

Summary of Significant Accounting Policies (Schedule of PP&E Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2016
Buildings | Minimum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	20 years
Buildings | Maximum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	31 years
Machinery and equipment | Minimum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	2 years
Machinery and equipment | Maximum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	12 years
Furniture and Fixtures | Minimum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	3 years
Furniture and Fixtures | Maximum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	7 years
Automobiles | Minimum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	4 years
Automobiles | Maximum
Property, Plant and Equipment
Property, Plant and Equipment Useful Life	5 years

Summary of Significant Accoun45

Summary of Significant Accounting Policies (Schedule of Intangible Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Useful life of intangibles	12 years	12 years
Product rights
Useful life of intangibles	12 years	12 years
Product rights | Minimum
Useful life of intangibles	5 years
Product rights | Maximum
Useful life of intangibles	15 years
Patents
Useful life of intangibles	10 years	10 years
Patents | Minimum
Useful life of intangibles	10 years
Patents | Maximum
Useful life of intangibles	20 years
Land-use rights
Useful life of intangibles	39 years	39 years
Land-use rights | Minimum
Useful life of intangibles	37 years
Land-use rights | Maximum
Useful life of intangibles	50 years

Business Acquisition (Narrative

Business Acquisition (Narrative) (Details) € in Thousands, $ in Thousands	Apr. 30, 2014EUR (€)	Apr. 30, 2014USD ($)	Aug. 31, 2016USD ($)item	Mar. 31, 2016USD ($)item	Jan. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015	Dec. 31, 2014USD ($)	Apr. 30, 2014USD ($)
Business Acquisition
Payment to Acquire Business, Gross						$ 12,461		$ 18,352
Useful life of intangibles						12 years	12 years
Goodwill related to acquisition of business						$ 391
International Medication Systems (UK) Limited
Business Acquisition
Number of Marketing Authorizations Acquired | item			33
Number of Different Injectable Chemical Entities | item			11
Payment to Acquire Business, Gross			$ 7,700
Marketing authorizations acquired			9,200
Manufacturing equipment acquired			100
Deferred tax liability assumed			$ 1,600
Useful life of intangibles			10 years
Hikma Pharmaceuticals PLC
Business Acquisition
Number of Different Injectable Chemical Entities | item				11
Payment to Acquire Business, Gross				$ 4,000
Useful life of intangibles				15 years
Number of Injectable Products Acquired | item				14
Assets acquired				$ 4,000
Merck Sharpe & Dohme's API
Business Acquisition
Purchase price	€ 24,800	$ 34,400
Manufacturing equipment acquired	6,800								$ 9,417
Assets acquired	30,400								42,098
Liabilities assumed	€ 5,580								$ 7,727
Number of Years Required to Transfer Starting Material						2 years
Letop
Business Acquisition
Purchase price					$ 1,700
Payment to Acquire Business, Gross					800
Deposit that ANP previously paid which was effectively eliminated upon the consummation of the transaction					900
Assets acquired					1,400
Liabilities assumed					$ 100

Business Acquisition (Acquisiti

Business Acquisition (Acquisition of Merck’s API Manufacturing Business) (Details) - Apr. 30, 2014 - Merck Sharpe & Dohme's API € in Thousands, $ in Thousands	EUR (€)	USD ($)
Business Acquisition
Purchase price	€ 24,800	$ 34,400
At Closing, April 2014	13,252	18,352
December 2,014	4,899	5,989
December 2,015	3,186	3,483
December 2,016	3,186	3,427
December 2,017	500	526
Total - estimated	€ 25,023	$ 31,777

Business Acquisition (Summary o

Business Acquisition (Summary of Estimated Fair Value of Assets Acquired and Liabilities Assumed) (Details) € in Thousands, $ in Thousands	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Apr. 30, 2014EUR (€)	Apr. 30, 2014USD ($)
Business Acquisition
Goodwill	$ 3,976	$ 3,726	$ 4,467
Merck Sharpe & Dohme's API
Business Acquisition
Inventory				€ 15,565	$ 21,554
Real property				4,800	6,647
Machinery & equipment				6,800	9,417
Intangibles				80	111
Goodwill				3,155	4,369
Total assets acquired				30,400	42,098
Accrued liabilities				2,425	3,358
Deferred tax liabilities				3,155	4,369
Total liabilities assumed				5,580	7,727
Total fair value of consideration transferred				€ 24,820	$ 34,371

Business Acquisition (Summary49

Business Acquisition (Summary of Pro Forma Financial Information) (Details) - Merck Sharpe & Dohme's API - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition
Net revenues	$ 212,745	$ 243,786
Net loss	$ (11,928)	$ 12,969
Diluted net loss per share (in Dollars per share)	$ (0.28)	$ 0.33

Revenue Recognition (Analysis o

Revenue Recognition (Analysis of the Chargeback Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue Recognition
Beginning balance	$ 15,217	$ 11,872
Provision related to sales made in the current period	166,987	162,238
Credits issued to third parties	(144,384)	(158,893)
Ending balance	$ 37,820	$ 15,217

Revenue Recognition (Analysis51

Revenue Recognition (Analysis of Product Return Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue Recognition
Beginning balance	$ 2,621	$ 2,408
Provision for product returns	1,753	1,675
Credits issued to third parties	(1,231)	(1,462)
Ending balance	3,143	$ 2,621
Sales not recognized in revenues due to insufficient information available to estimate a reasonable product return accrual	$ 500
Aggregate product return rate	1.10%	1.10%

Income (Loss) per Share (Narrat

Income (Loss) per Share (Narrative) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,379,984	12,240,467	11,371,891
Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities	$ 22.46
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		866,540	503,010
Employee Stock Purchase Plan (ESPP)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		61,766

Income (Loss) per Share (Calcul

Income (Loss) per Share (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Basic and dilutive numerator:
Net income (loss)	$ (2,742)	$ 3,890	$ 6,895	$ 2,489	$ 7,533	$ (3,008)	$ (6,647)	$ (665)	$ 10,532	$ (2,787)	$ (10,699)
Denominator:
Shares outstanding									45,375	44,961	41,957
Weighted-average shares outstanding—basic	46,104	45,398	44,957	45,041	45,085	45,310	44,849	44,601	45,375	44,961	41,957
Net effect of dilutive securities:
Incremental shares from equity awards									2,129
Weighted-average shares outstanding — diluted	46,104	47,953	45,968	46,810	46,709	45,310	44,849	44,601	47,504	44,961	41,957
Net income (loss) per share — basic	$ (0.06)	$ 0.09	$ 0.15	$ 0.06	$ 0.17	$ (0.07)	$ (0.15)	$ (0.01)	$ 0.23	$ (0.06)	$ (0.25)
Net income (loss) per share — diluted	$ (0.06)	$ 0.08	$ 0.15	$ 0.05	$ 0.16	$ (0.07)	$ (0.15)	$ (0.01)	$ 0.22	$ (0.06)	$ (0.25)

Segment Reporting (Selected Fin

Segment Reporting (Selected Financial Information by Reporting Segment) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments | segment									2
Net revenues:
Net Revenue	$ 63,543	$ 64,223	$ 68,033	$ 59,366	$ 76,912	$ 63,868	$ 53,853	$ 56,886	$ 255,165	$ 251,519	$ 210,461
Gross Profit:
Gross Profit	19,961	27,612	31,714	24,902	33,171	17,578	13,318	13,280	104,189	77,347	51,256
Operating expenses									88,497	84,245	69,239
Income (loss) from operations									15,692	(6,898)	(17,983)
Non-operating expenses									(746)	(3,466)	(165)
Income (loss) before income taxes									14,946	(10,364)	(18,148)
Finished Pharmaceutical Products
Net revenues:
Net Revenue	58,853	59,058	63,756	58,554	66,092	57,902	50,075	50,872	240,221	224,941	198,480
Gross Profit:
Gross Profit	21,057	28,621	30,598	25,824	29,357	19,302	12,634	12,853	106,100	74,146	52,724
API
Net revenues:
Net Revenue	4,690	5,165	4,277	812	10,820	5,966	3,778	6,014	14,944	26,578	11,981
Gross Profit:
Gross Profit	$ (1,096)	$ (1,009)	$ 1,116	$ (922)	$ 3,814	$ (1,724)	$ 684	$ 427	$ (1,911)	$ 3,201	$ (1,468)

Segment Reporting (Summary of N

Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 63,543	$ 64,223	$ 68,033	$ 59,366	$ 76,912	$ 63,868	$ 53,853	$ 56,886	$ 255,165	$ 251,519	$ 210,461
Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 58,853	$ 59,058	$ 63,756	$ 58,554	$ 66,092	$ 57,902	$ 50,075	$ 50,872	240,221	224,941	198,480
Finished Pharmaceutical Products | Enoxaparin
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									59,320	84,502	107,456
Finished Pharmaceutical Products | Naloxone
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									47,532	38,602	19,236
Finished Pharmaceutical Products | Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									36,600	30,260	23,195
Finished Pharmaceutical Products | Phytonadione
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									33,315	19,804	9,512
Finished Pharmaceutical Products | Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									25,661	14,936	8,853
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue									$ 37,793	$ 36,837	$ 30,228

Segment Reporting (Summary of R

Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue	$ 63,543	$ 64,223	$ 68,033	$ 59,366	$ 76,912	$ 63,868	$ 53,853	$ 56,886	$ 255,165	$ 251,519	$ 210,461
Long-Lived Assets	152,944				142,161				152,944	142,161
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue									249,007	243,295	198,480
Long-Lived Assets	104,110				100,404				104,110	100,404
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	35,085				28,547				35,085	28,547
FRANCE
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Revenue									6,158	8,224	$ 11,981
Long-Lived Assets	13,659				$ 13,210				13,659	$ 13,210
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 90								$ 90

Customer and Supplier Concent57

Customer and Supplier Concentration (Details) - Customer Concentration Risk [Member] - item	12 Months Ended			24 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016
Revenue, Major Customer [Line Items]
Number of major customers that are wholesale distributors	3
Accounts Receivable
Revenue, Major Customer [Line Items]
Number of major customers				5
Net Revenues
Revenue, Major Customer [Line Items]
Number of major customers	5	5	5
Actavis, Inc. | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers	1.00%	12.00%
Actavis, Inc. | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	14.00%	21.00%	30.00%
AmerisourceBergen | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers	30.00%	12.00%
AmerisourceBergen | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	21.00%	17.00%	15.00%
Cardinal Health | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers	28.00%	20.00%
Cardinal Health | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	22.00%	17.00%	14.00%
MannKind Corporation | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers	2.00%	13.00%
MannKind Corporation | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	3.00%	8.00%	2.00%
McKesson | Accounts Receivable
Revenue, Major Customer [Line Items]
Major Customers	19.00%	21.00%
McKesson | Net Revenues
Revenue, Major Customer [Line Items]
Major Customers	21.00%	22.00%	22.00%

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Values of the Company’s Financial Assets and Liabilities) (Details) - Recurring Basis - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Restricted short-term investments:
Fair value measurement	$ 37,472	$ 43,771
Money market accounts
Cash equivalents:
Cash equivalents	36,082	42,486
Certificates of deposit
Restricted short-term investments:
Restricted short-term investments	1,390	1,285
Level 1
Restricted short-term investments:
Fair value measurement	37,472	43,771
Level 1 | Money market accounts
Cash equivalents:
Cash equivalents	36,082	42,486
Level 1 | Certificates of deposit
Restricted short-term investments:
Restricted short-term investments	$ 1,390	$ 1,285

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements
Assets, Fair Value Adjustment	$ 0	$ 0
Liabilities, Fair Value Adjustment	$ 0	$ 0

Goodwill and Intangible Asset60

Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Feb. 28, 2017USD ($)item	Aug. 31, 2016USD ($)item	Mar. 31, 2016USD ($)item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Definite-lived intangible assets
Weighted-Average Life (Years)				12 years	12 years
Finite-Lived Intangible Assets, Gross				$ 43,173	$ 30,557
Accumulated Amortization				26,067	23,607
Finite-Lived Intangible Assets, Net				17,106	6,950
Indefinite-lived intangible assets
Goodwill recognized				3,976	3,726	$ 4,467
Subtotal, Original Cost				33,201	32,951
Subtotal, Net Book Value				33,201	32,951
Balance, Original Cost				76,374	63,508
Balance, Net Book Value				50,307	39,901
Payment to Acquire Business, Gross				12,461		18,352
Amortization expense related to Cortrosyn				2,517	1,938	1,920
Subsequent Event
Indefinite-lived intangible assets
Number of Injectable Products Sold | item	14
Sale price of intangible assets	$ 6,400
Finished Pharmaceutical Products
Indefinite-lived intangible assets
Goodwill recognized				3,976	3,726
Trademarks
Indefinite-lived intangible assets
Indefinite-lived intangible assets				$ 29,225	$ 29,225
Product rights
Definite-lived intangible assets
Weighted-Average Life (Years)				12 years	12 years
Finite-Lived Intangible Assets, Gross				$ 27,134	$ 27,134
Accumulated Amortization				24,461	22,679
Finite-Lived Intangible Assets, Net				2,673	4,455
Indefinite-lived intangible assets
Amortization expense related to Cortrosyn				$ 2,400	$ 1,800	$ 1,800
Acquired international product rights
Definite-lived intangible assets
Weighted-Average Life (Years)				10 years
Finite-Lived Intangible Assets, Gross				$ 8,632
Accumulated Amortization				359
Finite-Lived Intangible Assets, Net				$ 8,273
Acquired ANDAs
Definite-lived intangible assets
Weighted-Average Life (Years)				15 years
Finite-Lived Intangible Assets, Gross				$ 4,000
Accumulated Amortization				222
Finite-Lived Intangible Assets, Net				$ 3,778
Patents
Definite-lived intangible assets
Weighted-Average Life (Years)				10 years	10 years
Finite-Lived Intangible Assets, Gross				$ 293	$ 293
Accumulated Amortization				137	107
Finite-Lived Intangible Assets, Net				$ 156	$ 186
Land-use rights
Definite-lived intangible assets
Weighted-Average Life (Years)				39 years	39 years
Finite-Lived Intangible Assets, Gross				$ 2,540	$ 2,540
Accumulated Amortization				354	288
Finite-Lived Intangible Assets, Net				$ 2,186	$ 2,252
Other intangible assets
Definite-lived intangible assets
Weighted-Average Life (Years)				1 year	1 year
Finite-Lived Intangible Assets, Gross				$ 574	$ 590
Accumulated Amortization				534	533
Finite-Lived Intangible Assets, Net				$ 40	$ 57
International Medication Systems (UK) Limited
Definite-lived intangible assets
Weighted-Average Life (Years)		10 years
Indefinite-lived intangible assets
Payment to Acquire Business, Gross		$ 7,700
Marketing authorizations acquired		$ 9,200
Number of Different Injectable Chemical Entities | item		11
Hikma Pharmaceuticals PLC
Definite-lived intangible assets
Weighted-Average Life (Years)			15 years
Indefinite-lived intangible assets
Payment to Acquire Business, Gross			$ 4,000
Number of Injectable Products Acquired | item			14
Number of Different Injectable Chemical Entities | item			11

Goodwill and Intangible Asset61

Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets
Beginning balance	$ 3,726	$ 4,467
Goodwill related to acquisition of business	391
Currency translation and other adjustments	(141)	(741)
Ending balance	$ 3,976	$ 3,726

Goodwill and Intangible Asset62

Goodwill and Intangible Assets (Summary of Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets
2,017	$ 2,650
2,018	1,759
2,019	857
2,020	851
2,021	851
Thereafter	10,138
Finite-Lived Intangible Assets, Net	17,106	$ 6,950
Indefinite-lived intangibles	33,201
Balance, Net Book Value	$ 50,307	$ 39,901

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventories
Raw materials and supplies	$ 36,209	$ 29,904
Work in process	22,266	26,081
Finished goods	21,279	14,680
Total inventory, net	$ 79,754	$ 70,665

Property, Plant, and Equipmen64

Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 274,957	$ 254,419
Less accumulated depreciation and amortization	(122,013)	(112,258)
Total property, plant, and equipment, net	152,944	142,161
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	85,283	82,309
Leasehold improvement
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	24,619	23,392
Land
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	6,857	6,895
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	111,041	108,442
Furniture, fixtures, and automobiles
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	15,113	13,439
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 32,044	$ 19,942

Property, Plant, and Equipmen65

Property, Plant, and Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 12,047	$ 11,314	$ 12,528
Interest Costs Capitalized	800	1,100	$ 1,200
Capitalized manufacturing equipment for specific use	274,957	254,419
Equipment | Primatene Mist
Property, Plant and Equipment [Line Items]
Capitalized manufacturing equipment for specific use	$ 2,600	$ 2,900

Debt (Schedule of Debt) (Detail

Debt (Schedule of Debt) (Details) $ in Thousands, € in Millions	Dec. 31, 2016EUR (€)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument
Equipment under Capital Leases		$ 1,614	$ 802
Total debt and capital leases		37,722	41,099
Less current portion of long-term debt and capital leases		5,366	10,934
Long-term debt and capital leases, net of current portion		32,356	30,165
Mortgage Payable Matured January 2016 | East West Bank
Debt Instrument
Long Term Debt			3,725
Mortgage Payable Matured September 2016 | East West Bank
Debt Instrument
Long Term Debt			2,211
Equipment Loan - Due April 2017 | East West Bank
Debt Instrument
Long Term Debt		433	1,700
Equipment Loan - Due January 2019 | East West Bank
Debt Instrument
Long Term Debt		3,208	4,748
Mortgage Payable - Due February 2021 | East West Bank
Debt Instrument
Long Term Debt		3,660
Equipment Credit Line Due September 2021 | East West Bank
Debt Instrument
Long Term Debt		2,882
Mortgage Payable - Due October 2026 | East West Bank
Debt Instrument
Long Term Debt		3,582
Acquisition Loan - Due April 2019 | Cathay Bank
Debt Instrument
Long Term Debt		17,079	19,012
Mortgage Payable - Due April 2021 | Cathay Bank
Debt Instrument
Long Term Debt		4,367	4,460
French Government Loan - Due March 2018 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt		30	46
French Government Loan - Due June 2020 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt		99	128
French Government Loan - Due July 2021 | Seine-Normandie Water Agency
Debt Instrument
Long Term Debt		262	325
Note Payable To Merck
Debt Instrument
Long Term Debt	€ 0.5	$ 506	$ 3,942

Debt (Narrative) (Details)

Debt (Narrative) (Details) € in Millions

Mar. 01, 2016

Jan. 31, 2015USD ($)

Jan. 05, 2015USD ($)

Jun. 01, 2014

Apr. 30, 2014EUR (€)

Apr. 22, 2014USD ($)

Sep. 15, 2006USD ($)building

Dec. 31, 2016EUR (€)

Dec. 31, 2016USD ($)

Sep. 30, 2016USD ($)

Mar. 31, 2016USD ($)

Dec. 31, 2015EUR (€)

Dec. 31, 2015USD ($)

Jan. 31, 2015EUR (€)item

Jul. 31, 2013

Mar. 31, 2013

Dec. 31, 2016USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2010USD ($)building

Dec. 31, 2016USD ($)

Jan. 08, 2016USD ($)building

Jan. 31, 2015USD ($)item

Jan. 13, 2015USD ($)

Apr. 30, 2014USD ($)

Dec. 31, 2013USD ($)

Jul. 05, 2013USD ($)

Mar. 15, 2013USD ($)

Apr. 10, 2012USD ($)

Mar. 31, 2012USD ($)

Mar. 05, 2012USD ($)

Mar. 05, 2007USD ($)

Debt

Proceeds from borrowing under lines of credit

$ 25,000,000

Long-term Debt and Capital Lease Obligations

$ 30,165,000

$ 32,356,000

Payment to Acquire Business, Gross

$ 12,461,000

$ 18,352,000

Capital Leased Assets, Gross

1,500,000

2,000,000

Equipment Loan - Due April 2017 | East West Bank

Debt

Principal amount

$ 4,900,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,000,000

Long Term Debt

1,700,000

433,000

Equipment Loan - Due April 2017 | East West Bank | Prime Rate

Debt

Debt Instrument, Basis Spread on Variable Rate

0.25%

Line of Credit Facility - Due September 2017 | East West Bank

Debt

Line of Credit Facility, Maximum Borrowing Capacity

$ 15,000,000

$ 10,000,000

Line of Credit outstanding

$ 0

Equipment Loan - Due January 2019 | East West Bank

Debt

Principal amount

$ 6,200,000

Debt Instrument, Interest Rate, Stated Percentage

4.48%

4.48%

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,000,000

Proceeds from borrowing under lines of credit

$ 6,200,000

Long Term Debt

4,748,000

$ 3,208,000

Equipment Loan - Due January 2019 | East West Bank | Prime Rate

Debt

Debt Instrument, Basis Spread on Variable Rate

0.25%

Mortgage Payable - Due February 2021 | East West Bank

Debt

Principal amount

$ 4,500,000

$ 3,700,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 3,800,000

$ 3,300,000

Debt Instrument, Interest Rate, Stated Percentage

4.39%

4.39%

Long Term Debt

$ 3,660,000

Mortgage Payable - Due February 2021 | East West Bank | Rancho Cucamonga, California

Debt

Number of Buildings Securing Loan | building

1

1

Mortgage Payable - Due February 2021 | East West Bank | Chino, California

Debt

Number of Buildings Securing Loan | building

1

Equipment Credit Line Due September 2021 | East West Bank

Debt

Line of Credit Facility, Maximum Borrowing Capacity

$ 5,000,000

Line of Credit outstanding

2,900,000

Draw down period

18 months

Term of loan after draw down period expires

48 months

Long Term Debt

2,882,000

Mortgage Payable - Due October 2026 | East West Bank

Debt

Long Term Debt

3,582,000

Mortgage Payable - Due October 2026 | East West Bank | Rancho Cucamonga, California

Debt

Principal amount

$ 2,800,000

$ 3,600,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,200,000

$ 2,900,000

Number of Buildings Securing Loan | building

1

Debt Instrument, Interest Rate, Stated Percentage

4.15%

Mortgage Payable - Due October 2026 | East West Bank | LIBOR | Rancho Cucamonga, California

Debt

Debt Instrument, Basis Spread on Variable Rate

2.50%

2.75%

Line of Credit Facility - Due May 2018 | Cathay Bank

Debt

Line of Credit Facility, Maximum Borrowing Capacity

$ 20,000,000

Line of Credit outstanding

0

Acquisition Loan - Due April 2019 | Cathay Bank

Debt

Principal amount

$ 21,900,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 12,000,000

Debt Instrument, Term

120 months

Debt Instrument Loan Collateral Percentage

65.00%

Debt Instrument Covenant Period To Discharge Final Judgment

30 days

Long Term Debt

19,012,000

17,079,000

Mortgage Payable - Due April 2021 | Cathay Bank

Debt

Principal amount

$ 4,600,000

$ 5,300,000

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 3,900,000

Debt Instrument, Interest Rate, Stated Percentage

5.42%

Long Term Debt

4,460,000

4,367,000

French Government Loans | Seine-Normandie Water Agency

Debt

Principal amount

€ 0.6

$ 700,000

Number of Loans with Government Agency | item

3

3

Debt Instrument, Periodic Payment, Interest

$ 0

Notes Payable

€ 0.4

400,000

Note Payable To Merck

Debt

Principal amount

€ 11.6

$ 16,000,000

Debt Instrument, Term

4 years

Payment to Acquire Business, Gross

3.2

$ 3,400,000

€ 3.2

3,500,000

Long Term Debt

€ 0.5

3,942,000

506,000

Equipment under Capital Leases

Debt

Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation

$ 700,000

$ 200,000

Minimum | Equipment Loan - Due April 2017 | East West Bank

Debt

Debt Instrument, Interest Rate, Stated Percentage

3.50%

Minimum | Mortgage Payable - Due February 2021 | East West Bank | Prime Rate

Debt

Debt Instrument, Basis Spread on Variable Rate

5.00%

Minimum | Line of Credit Facility - Due May 2018 | Cathay Bank | Prime Rate

Debt

Debt Instrument, Interest Rate, Stated Percentage

4.00%

Minimum | Acquisition Loan - Due April 2019 | Cathay Bank | Prime Rate

Debt

Debt Instrument, Basis Spread on Variable Rate

4.00%

Minimum | French Government Loans | Seine-Normandie Water Agency

Debt

Debt Instrument, Term

3 years

Minimum | French Government Loans | Seine-Normandie Water Agency | Prime Rate

Debt

Debt Instrument, Interest Rate, Stated Percentage

4.00%

4.00%

Minimum | Note Payable To Merck

Debt

Debt Instrument, Interest Rate, Stated Percentage

3.00%

3.00%

Minimum | Note Payable To Merck | Prime Rate

Debt

Debt Instrument, Interest Rate, Stated Percentage

4.00%

4.00%

Maximum | French Government Loans | Seine-Normandie Water Agency

Debt

Debt Instrument, Term

6 years

Debt (Long-Term Debt Maturities

Debt (Long-Term Debt Maturities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt
2,017	$ 5,004
2,018	4,702
2,019	14,155
2,020	1,075
2,021	7,906
Thereafter	3,188
Total long-term Debt	36,030
Capital Leases
2,017	362
2,018	379
2,019	396
2,020	388
2,021	167
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Total	1,692
Total debt and capital leases	$ 37,722	$ 41,099

Income Taxes (Summary of Income

Income Taxes (Summary of Income (Loss) Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income (loss) before income taxes:
United States	$ 20,888	$ (4,344)	$ (12,946)
Foreign	(5,942)	(6,020)	(5,202)
Income (loss) before income taxes	$ 14,946	$ (10,364)	$ (18,148)

Income Taxes (Summary of the Pr

Income Taxes (Summary of the Provision (Benefit) for Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current provision (benefit):
Federal	$ 7,279	$ 82	$ (131)
State	344	73	193
Foreign	787	(112)	1,388
Total current provision (benefit)	8,410	43	1,450
Deferred provision (benefit):
Federal	(2,491)	(5,222)	(4,309)
State	(1,066)	(1,250)	(1,699)
Foreign	(439)	(1,148)	(2,891)
Total deferred provision (benefit)	(3,996)	(7,620)	(8,899)
Total provision (benefit) for income taxes	$ 4,414	$ (7,577)	$ (7,449)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of the Statutory Federal Income Tax Rate to the Effective Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of the statutory federal income tax rate to the Companys effective rate:
Statutory federal income tax (benefit)	35.00%	35.00%	35.00%
State tax expense, net of federal tax benefit	(3.10%)	(7.40%)	(5.40%)
Foreign tax rate differences	1.80%	(1.10%)	1.80%
Foreign valuation allowance	14.40%	(23.30%)
Qualified production activities deduction	(8.70%)
Research and development credits	(11.70%)	(15.40%)	(6.40%)
Share-based compensation	3.00%	7.70%	4.00%
Other	(1.20%)	1.40%
Effective tax rate (benefit)	29.50%	(73.10%)	(41.00%)

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets/Liabilities) (Details) $ in Thousands, € in Millions	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Apr. 30, 2014EUR (€)	Apr. 30, 2014USD ($)
Deferred tax assets:
Net operating loss carryforward	$ 4,698	$ 8,616
State income taxes	393	300
Inventory capitalization and reserve	7,368	5,365
Deferred revenue		584
Accrued payroll and benefits	1,813	1,793
Share-based compensation	10,545	10,125
Research and development credits	9,668	13,071
Alternative minimum tax	895	529
Accrued professional fees	1,333	987
Product return allowance	1,758	1,545
Accrued chargebacks	15,158	5,910
Bad debt reserve	95	253
Intangibles	3,370	3,370
Accrued for workers’ compensation insurance	1,409	1,035
Total deferred tax assets	58,503	53,483
Deferred tax liabilities:
Depreciation/amortization	13,763	15,065
Intangibles	8,208	5,430
Federal impact of state deferred taxes	3,784	3,380
Other	158	1,241
Total deferred tax liabilities	25,913	25,116
Valuation allowance	(3,044)	(923)	€ (3.2)	$ (4,400)
Net deferred tax assets	$ 29,546	$ 27,444

Income Taxes (Net Operating Los

Income Taxes (Net Operating Loss Carryforwards and Tax Credits) (Details) $ in Millions	Dec. 31, 2016USD ($)
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 16.7

Income Taxes (Valuation Allowan

Income Taxes (Valuation Allowance) (Details) $ in Thousands, € in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2015EUR (€)	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Apr. 30, 2014EUR (€)	Apr. 30, 2014USD ($)
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Valuation Allowance			$ 3,044	$ 923	€ 3.2	$ 4,400
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	€ (3.2)	$ (3,300)
Accumulated undistributed foreign earnings			$ 14,900	$ 7,100
Domestic Tax Authority
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Expiration Date			Dec. 31, 2035
Domestic Tax Authority | Research and Development Tax Credit
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount			$ 2,600
Domestic Tax Authority | AMT
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount			500
State and Local Jurisdiction | California Franchise Tax Board | Research and Development Tax Credit
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount			$ 11,700

Income Taxes (Reconciliation 75

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at the beginning of the year	$ 5,595	$ 4,783	$ 4,186
Additions based on tax positions related to prior years	188
Additions based on tax positions related to the current year	903	812	655
Deductions based on statute of limitations			(58)
Balance at the end of the year	6,686	5,595	$ 4,783
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	5,900
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	1,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 300	$ 100

Income Taxes (Uncertain Income

Income Taxes (Uncertain Income Tax Positions - Narrative) (Details)	12 Months Ended
	Dec. 31, 2016
Tax Year 2007 | California Franchise Tax Board
Income Tax Contingency [Line Items]
Income Tax Examination, Year under Examination	2,007
Tax Year 2008 | California Franchise Tax Board
Income Tax Contingency [Line Items]
Income Tax Examination, Year under Examination	2,008
Tax Year 2009 | California Franchise Tax Board
Income Tax Contingency [Line Items]
Income Tax Examination, Year under Examination	2,009
Domestic Tax Authority | Tax Year 2012
Income Tax Contingency [Line Items]
Open Tax Year	2,013
Domestic Tax Authority | Tax Year 2013
Income Tax Contingency [Line Items]
Open Tax Year	2,014
Domestic Tax Authority | Tax Year 2014
Income Tax Contingency [Line Items]
Open Tax Year	2,015
State and Local Jurisdiction | Earliest Tax Year
Income Tax Contingency [Line Items]
Open Tax Year	2,007
State and Local Jurisdiction | Latest Tax Year
Income Tax Contingency [Line Items]
Open Tax Year	2,015

Stockholders' Equity (Common an

Stockholders' Equity (Common and Preferred Stock) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 25, 2014	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Subsidiary, Sale of Stock [Line Items]
Payments of Stock Issuance Costs					$ 1,920
Allocated Share-based Compensation Expense			$ 15,124	$ 12,815	$ 9,280
Common stock; authorized shares			300,000,000	300,000,000
Common stock par value (in dollars per share)			$ 0.0001	$ 0.0001
Preferred stock, shares authorized			20,000,000	20,000,000
Preferred stock, par value (in dollars per share)			$ 0.0001	$ 0.0001
Preferred stock, shares issued			0	0
Preferred stock, shares outstanding			0	0
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	5,840,000
Share Price (in Dollars per share)	$ 7
Proceeds from issuance of common stock	$ 40,900
Payments of Stock Issuance Costs	$ 6,200
Proceeds from Issuance Initial Public Offering, Net of Issuance Costs (in Dollars)		$ 34,700
IPO [Member] | Underwriter
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	1,200,000

Stockholders' Equity (The 2015

Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) - shares	1 Months Ended	12 Months Ended
	Jan. 31, 2017	Dec. 31, 2016	Mar. 18, 2015
The 2015 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)		4,164,625	5,300,296
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)		5,000,000
Equity Incentive Plan, Term		10 years
Share Based Compensation Arrangement By Share Based Payment Award Potential Number of Additional Shares Authorized (in Shares)		3,000,000
Share Based Compensation Arrangement by Share Based Payment Award Potential Annual Increase in Shares, Percentage		2.50%
The 2015 Equity Incentive Plan | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,156,216
Amended and Restated 2005 Equity Plan [Member] | Existing Employees | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Amended and Restated 2005 Equity Plan [Member] | Existing Employees | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Amended and Restated 2005 Equity Plan [Member] | New Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years

Stockholders' Equity (2014 Empl

Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation		$ 15,124	$ 12,815	$ 9,280
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan, Offering Duration, Maximum	27 months
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)		248,587
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)		1,751,413
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	2,000,000
Allocated share based compensation		$ 500	$ 400

Stockholders' Equity (Share Buy

Stockholders' Equity (Share Buyback Program) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Nov. 07, 2016	Nov. 10, 2015	Nov. 06, 2014
Equity, Class of Treasury Stock [Line Items]
Stock buyback program, authorized amount						$ 10,000
Treasury Stock, Value, Acquired, Cost Method	$ 9,908	$ 9,865	$ 345
November 2014 Share Repurchase Plan
Equity, Class of Treasury Stock [Line Items]
Stock buyback program, authorized amount				$ 20,000	$ 10,000
Treasury Stock, Shares, Acquired (in Shares)	759,067	735,679
Treasury Stock, Value, Acquired, Cost Method	$ 9,900	$ 9,900

Stockholders' Equity (Key Assum

Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity
Average overall forfeiture rate	7.00%	8.00%	8.00%
Average volatility	30.40%	27.10%	29.90%
Risk-free interest rate	1.50%	1.30%	1.70%
Weighted-average expected life in years	5 years 6 months	4 years 6 months	5 years

Stockholders' Equity (Summary o

Stockholders' Equity (Summary of Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Options
Outstanding Options, Beginning of period	12,240,467
Options granted	2,395,789
Options exercised	(1,465,539)
Options cancelled	(178,932)
Options expired	(461,488)
Outstanding Options, End of period	12,530,297	12,240,467
Exercisable at the end of period	7,938,110
Weighted-Average Exercise Price
Outstanding Exercise Price (in dollars per share)	$ 15.41
Options granted (in dollars per share)	12.19
Options exercised (in dollars per share)	13.88
Options cancelled (in dollars per share)	13.50
Options expired (in dollars per share)	26.99
Outstanding Exercise Price (in dollars per share)	14.57	$ 15.41
Exercisable at the end of period	$ 15.15
Additional Disclosures
Outstanding Contractual Term (in Years)	4 years 3 months 26 days
Outstanding Intrinsic Value	$ 60,292
Exercisable at the end of period (in Years)	2 years 10 months 10 days
Exercisable aggregate intrinsic value	$ 38,041
Allocated share based compensation	$ 15,124	$ 12,815	$ 9,280
The 2015 Plan and 2005 Plan [Member] | Minimum
Additional Disclosures
Outstanding Contractual Term (in Years)	5 years
Vesting term	3 years
The 2015 Plan and 2005 Plan [Member] | Maximum
Additional Disclosures
Outstanding Contractual Term (in Years)	10 years
Vesting term	5 years
Employee Stock Option
Additional Disclosures
Allocated share based compensation	$ 8,000	7,900	6,700
Employee Stock Option | Board of Directors
Additional Disclosures
Allocated share based compensation	$ 700	$ 500	$ 600

Stockholders' Equity (Informati

Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity
Weighted-average grant date fair value (in Dollars per share)	$ 3.42	$ 3.45	$ 4.02
Intrinsic value of options exercised	$ 7,446	$ 3,247	$ 144
Cash received	20,338	13,502	571
Total fair value of the options vested during the year	$ 8,654	$ 6,634	$ 6,407

Stockholders' Equity (Summary84

Stockholders' Equity (Summary of Nonvested Options) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Options
Nonvested at beginning of period	5,202,095
Options granted	2,395,789
Options vested	(2,826,765)
Options forfeited	(178,932)
Nonvested at end of period	4,592,187	5,202,095
Weighted-Average Grant Date Fair Value
Nonvested at beginning of period (in dollars per share)	$ 3.44
Options granted (in dollars per share)	3.42	$ 3.45	$ 4.02
Options vested (in dollars per share)	3.06
Options forfeited (in dollars per share)	4.68
Nonvested at end of period (in dollars per share)	$ 3.61	$ 3.44
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 10.9
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 1 month 6 days

Stockholders' Equity (Restricte

Stockholders' Equity (Restricted Stock Units) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Contractual Term (in Years)	4 years 3 months 26 days
Allocated share based compensation	$ 15,124	$ 12,815	$ 9,280
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares)	1
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Allocated share based compensation	$ 5,200	3,400	1,600
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 3 months 18 days
Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 10,100
Maximum | Amended and Restated 2005 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Board of Directors | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	$ 700	$ 500	$ 400

Stockholders' Equity (Informa86

Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Total RSUs outstanding at the beginning of the period	866,540
RSUs granted	732,021
RSUs forfeited	(54,381)
Common stock delivered for RSUs	(108,817)
RSUs surrendered for taxes	(219,577)
Total RSUs outstanding at the end of the period	1,215,786
Total Fair Market Value of RSUs Issued
RSUs granted (in Dollars) | $	$ 8,646

Stockholders' Equity (Equity Aw

Stockholders' Equity (Equity Awards to Consultants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	$ 15,124	$ 12,815	$ 9,280
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	$ 100	$ 200

Stockholders' Equity (Share-Bas

Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	$ 15,124	$ 12,815	$ 9,280
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	2,967	2,526	1,678
Selling, distribution and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	220	192	137
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	10,865	9,185	6,800
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share based compensation	$ 1,072	$ 912	$ 665

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Benefits
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Contribution Vesting Period	4 years
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 1	$ 0.7	$ 0.7
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.75%	1.75%
Defined Benefit Plan, Benefit Obligation	$ 1.7	$ 1.6
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	0.4		0.2
Pension Expense	$ 0.2	$ 0.1	$ 0.2

Commitments and Contingencies90

Commitments and Contingencies (Distribution Agreement with Actavis, Inc) (Details) - Distribution Agreement - Actavis, Inc. - Enoxaparin - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2012	May 31, 2005
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from Customers		$ 4.5
Deferred Revenue	$ 4.5
Deferred Revenue, Period for Recognition	7 years

Commitments and Contingencies91

Commitments and Contingencies (Supply Agreement with MannKind Corporation) (Details) € in Millions, $ in Millions	Oct. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016EUR (€)	Dec. 31, 2015EUR (€)	Jul. 31, 2014EUR (€)	Jul. 31, 2014USD ($)
Supply Commitment [Line Items]
Supply Commitment, Cancellation Fee Recognized | $		$ 1.5
MannKind Corporation | Supply Commitment
Supply Commitment [Line Items]
Supply commitment in fourth quarter of 2017			€ 2.7
Supply commitment in 2018			8.9
Supply commitment in 2019			11.6
Supply commitment in 2020 and 2021			15.5
Supply commitment in 2022 and 2023			19.4
Long-term Supply Commitment, Optional Renewal Period		2 years
Supply Agreement Renewal Notice Period		12 months
MannKind Corporation | Supply Commitment | Recombinant Human Insulin (RHI)
Supply Commitment [Line Items]
Supply commitment annual amount committed			€ 23.3	€ 27.1	€ 120.1	$ 146
Supply Commitment, Number of Years Committed		5 years
Deferred Revenue					€ 11	$ 14
Supply Commitment, Cancellation Fee | $	$ 0.8
Sales | $		$ 6.8

Commitments and Contingencies92

Commitments and Contingencies (Collaboration Agreement) (Details) - Development agreement - Drug delivery system item in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)item
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Agreement, Upfront Payment	$ 0.5
Collaborative Agreement, Milestone Payments	1.2
Collaborative Agreement, Contingent Obligation	$ 0.8
Collaborative Agreement, Contingent Purchase Obligation First 12 Months, Units | item	1
Purchase period	12 months

Commitments and Contingencies93

Commitments and Contingencies (Operating Lease Agreements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 3,400	$ 3,300	$ 3,100
2,017	3,038
2,018	2,366
2,019	1,596
2,020	764
2,021	53
Operating Leases, Future Minimum Payments Due, Total	$ 7,817
Minimum
Operating Leased Assets [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term	1 year
Maximum
Operating Leased Assets [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term	6 years

Commitments and Contingencies94

Commitments and Contingencies (Purchase Commitments) (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Nov. 30, 2012	Jan. 31, 2010	Dec. 31, 2016
ANP
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase Commitments Amount Fulfilled			$ 61
Commitments to Purchase Equipment and Raw Materials
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Long-term Purchase Commitment, Amount			$ 41.9
Commitment to develop land | ANP
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Contractual Obligation	$ 15
Land-use rights | Commitment to invest | ANP
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Finite-lived Intangible Assets Acquired	$ 1.3	$ 1.2

Litigation (Details)

Litigation (Details) $ in Millions	May 09, 2016USD ($)	May 04, 2016item	Apr. 07, 2015USD ($)	Oct. 31, 2011USD ($)	Sep. 21, 2011item
Enoxaparin Patent Litigation
Loss Contingencies [Line Items]
Fees and costs relating to a discovery motion	$ 0.4
False Claims Act Litigation
Loss Contingencies [Line Items]
Number of orders issued by district court | item		3
Eva Hernandez vs International Medication Systems Limited
Loss Contingencies [Line Items]
Litigation Settlement, Amount			$ 3.2
Pending Litigation [Member] | Enoxaparin Patent Litigation
Loss Contingencies [Line Items]
Number of Alleged Patent Infringements | item					2
Litigation, Plaintiff Preliminary Injunction Bond, Amount				$ 100.1

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Millions	1 Months Ended
	Mar. 31, 2017USD ($)	Feb. 28, 2017USD ($)item
Subsequent Events
Number of Injectable Products Sold | item		14
Sale price of intangible assets		$ 6.4
Proceeds received from sale of ANDAs		1
Remaining Amount to be Paid Upon Completion of Certain Milestones		$ 5.4
Number of Days Upon Which Remainder of Payment is Due after Milestone Date		30 days
Royalty Fee Percentage		2.00%
Indemnification Liability Payable		$ 0.6
Epinephrine
Subsequent Events
Net revenues recognized	$ 18.6
Cost of revenues	$ 3.3

Quarterly Financial Data (Una97

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Condensed Income Statements, Captions [Line Items]
Total net revenues	$ 63,543	$ 64,223	$ 68,033	$ 59,366	$ 76,912	$ 63,868	$ 53,853	$ 56,886	$ 255,165	$ 251,519	$ 210,461
Gross profit	19,961	27,612	31,714	24,902	33,171	17,578	13,318	13,280	104,189	77,347	51,256
Net (loss) income	$ (2,742)	$ 3,890	$ 6,895	$ 2,489	$ 7,533	$ (3,008)	$ (6,647)	$ (665)	$ 10,532	$ (2,787)	$ (10,699)
Weighted-average shares used to compute net income (loss) per share:
Basic (in Shares)	46,104	45,398	44,957	45,041	45,085	45,310	44,849	44,601	45,375	44,961	41,957
Diluted (in Shares)	46,104	47,953	45,968	46,810	46,709	45,310	44,849	44,601	47,504	44,961	41,957
Net income (loss) per share:
Basic (in Dollars per share)	$ (0.06)	$ 0.09	$ 0.15	$ 0.06	$ 0.17	$ (0.07)	$ (0.15)	$ (0.01)	$ 0.23	$ (0.06)	$ (0.25)
Diluted (in Dollars per share)	$ (0.06)	$ 0.08	$ 0.15	$ 0.05	$ 0.16	$ (0.07)	$ (0.15)	$ (0.01)	$ 0.22	$ (0.06)	$ (0.25)
Finished Pharmaceutical Products
Condensed Income Statements, Captions [Line Items]
Total net revenues	$ 58,853	$ 59,058	$ 63,756	$ 58,554	$ 66,092	$ 57,902	$ 50,075	$ 50,872	$ 240,221	$ 224,941	$ 198,480
Gross profit	21,057	28,621	30,598	25,824	29,357	19,302	12,634	12,853	106,100	74,146	52,724
API
Condensed Income Statements, Captions [Line Items]
Total net revenues	4,690	5,165	4,277	812	10,820	5,966	3,778	6,014	14,944	26,578	11,981
Gross profit	$ (1,096)	$ (1,009)	$ 1,116	$ (922)	$ 3,814	$ (1,724)	$ 684	$ 427	$ (1,911)	$ 3,201	$ (1,468)

Quarterly Financial Data (Una98

Quarterly Financial Data (Unaudited) (Narrative) (Details) $ in Millions	3 Months Ended
	Dec. 31, 2015USD ($)
Quarterly Financial Data [Abstract]
Decrease to net income due to not recognizing non-operating expense for certain foreign currency transactions	$ 1.1